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Abstract
VARIATION AND MODULATION OF MICRORNAS IN PROSTATE CANCER AND
BIOLOGICAL FLUIDS
By Sarah Joy Seashols, Ph.D.
A dissertation) submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Biochemistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2013
Major Director: Zendra Elizabeth Zehner, PhD. Professor, Department of Biochemistry
& Molecular Biology

Prostate cancer is the second-most diagnosed and fatal carcinoma for males in
the United States, and better diagnostic markers and potential therapies are needed.
microRNAs are small, single-stranded RNA molecules that affect protein expression at
the translational level, and dysregulation can dramatically affect cell metabolism.
Comparison of 736 microRNA expression levels between the poorly metastatic SV40T
immortalized prostate epithelial cell line P69 to its highly tumorigenic and metastatic
subline M12 identified 231 miRs that were overexpressed and 150 miRs that showed
loss of expression in the M12 cell line. Further evaluation of fourteen identified miRs
was accomplished using other prostate cell lines as well as laser-capture
microdissected prostate samples. Inhibition of miR-147b was found to affect
proliferative, migratory and invasive capabilities of M12 cells, and reduced tumour

xxv

growth in nude athymic mice. AATF, an activator of the cell-cycle inhibitor p21, was
identified as a target. Overexpression of miR-9 was found to affect the epithelial to
mesenchymal transition through suppression of e-cadherin, a protein characterized as
lost in EMT, as well as suppression of SOCS5, an attenuator of JAK-STAT signaling.
Inhibition of miR-9 resulted in reduction of migratory and invasive potential, and
significant reduction of tumorigenesis and metastases in male nude athymic mice.
miR-17-3p was previously identified as down-regulated in prostate cancer and
loss of miR-17-3p shown to cause vimentin transcriptional activation. Reverse phase
microarray analysis (RPMA) identified c-KIT as a potential second mRNA target for
miR-17-3p. miR-17-3p was shown to modulate not only protein levels, but also
messenger RNA levels of c-KIT. Four miR-17-3p binding sites in the c-KIT mRNA were
identified. Thus, a number of microRNAs involved in prostate cancer were identified,
and their targets found to be highly relevant to tumour progression and could potentially
be used as targets for therapy or diagnostics.
Stability of microRNAs in forensically relevant biological fluids was evaluated
through heat treatment, ultraviolet radiation, and chemical treatment. The dried body
fluids showed some susceptibility to harsh treatment, but in most cases microRNAs
were still detectable in the samples. microRNAs could represent a highly stable species
for body fluid identification methods in forensic science.

I.

The prostate and incidence of cancer
The prostate is an exocrine organ located at the bladder-urethral junction that
serves to secrete an alkaline fluid that makes up 50-70% of seminal fluid. This fluid is
composed of nutrients and other compounds that facilitate spermatozoa activation,
survival and genomic integrity1. As a ductal gland, the prostate consists of multiple
lobes in which epithelial cells secrete their expressed products into glandular lumens,
and are compressed by the pelvic floor muscles during ejaculation to secrete the
prostatic fluid along with spermatozoa stored in the ejaculatory ducts into the urethra.
Prostate cancer (CaP) is the most common cancer for men in the United States
other than skin cancer, and the second leading cause of cancer deaths in the US, with
over 29,000 fatalities each year2. While two-thirds of the prostate cancers diagnosed
are indolent, wherein the tumour grows so slowly that the diagnosed male will likely die
of other causes before the carcinoma develops to a dangerous level, the other one-third
of diagnosed prostatic neoplasias are highly aggressive and metastasize readily to bone
and brain3,4.
Diagnosis of Prostate Cancer
The current standard for diagnosis of a potential prostate cancer diagnosis is use
of the prostate-specific antigen (PSA) test as a screening test, followed by manual
examination and ultrasound-guided transrectal biopsy5. PSA is a protein that is
produced in the prostate, and is normally found in high levels in seminal fluid, with lower
levels in male urine, and also in ultra-low levels in breastmilk, amniotic fluid,
cerebrospinal fluid, and other minor fluids6. Identification of PSA in the bloodstream has
1

been shown to be indicative of abnormal prostate growth2,3,6-8. Mechanistically, PSA
leaks into the bloodstream as the tumour both increases PSA production, and perturbs
the glandular form of the prostate, resulting in leakage of the overexpressed PSA into
the bloodstream9.
Before the implementation of PSA testing in the US in 1979, prostate cancer
diagnosis was made via a prostate examination only. Diagnosis using physical
examination often was only positive after the tumour was well-advanced, and thus
prostate cancer was often progressed to the point that chemotherapeutics were not
significantly effective. PSA level analysis was first used for monitoring therapeutic
outcomes10. However, further research showed that it could also be used for diagnosis,
and upon implementation of PSA screening, death rates for prostate cancer have
dropped 4% per year.
A blood PSA level of 4.0 ng/mL is considered to be abnormal in the United
States. PSA screening is not recommended for men of limited life expectancy, which is
typically classified as men 75 years or older, due to the nature of the very common
indolent form of prostate cancer8. In a 5-year DOD study, of 295,645 men included in
the analysis, 8.5% of the men evaluated had an abnormally high PSA level. Of the 67%
who did not have a biopsy, 0.1% died of prostate cancer. Of the 33% that had a biopsy
performed, 5220 (62.8%) were diagnosed with high-risk prostate cancer and were
treated. 3.5% of the 1161 diagnosed with low-risk CaP died from prostate cancer, an
average death rate for cohorts with or without treatment8. Thus, this and multiple
additional studies have shown that the intervention rate is well above that which is
necessary4.
2

Interventions tend to have drastic consequences for the diagnosed male; radical
prostatectomies, cryosurgery, and androgen ablation therapy significantly affect patient
quality of life through high levels of incontinence, psychological, and sexual side
effects3. Thus, the identification of new screening practices is critical to diagnosing not
only prostate cancer, but also differentiating between the aggressive and indolent forms
of the disease.
Transmission of genetic predisposition for prostate cancer
While high incidences of prostate cancer are common in those of Northern
European and African American descent, native Africans do not suffer such high
incidences, although it could also be underestimated due to lack of surveillance 7.
Additional evidence indicates that the susceptibility is Northern European in origin,
specifically of Swedish and/or Scandinavian origin, and follows the historical migration
routes of the Scandinavian people, with a higher incidence on the coasts of continents.
The high incidence seen in African Americans as compared to their native African
counterparts is most likely due to low levels of Northern European inter-breeding7, but
diet could also have an additive effect11. Likewise, men of Asian descent do not
develop malignancies at high rates7.
As may be expected from the observed ethnic disparities, monozygotic twin
studies have shown that inheritance of the predisposition for prostate cancer is real12.
Additionally, evaluation of paternal and maternal histories show similar inheritance
patterns, which indicates autosomal transmission4,13,14. Recent genome-wide
association studies (GWAS) have identified forty-six SNPs that show enhanced

3

susceptibility to CaP; studies are currently underway to evaluate both diagnostic
possibilities as well as treatment protocols based on those loci13.
Prostate Cancer tumorigenesis & histopathology
Protate cancer, like breast cancer, is the tumorigenesis of a glandular tissue. As
such, the carcinoma begins in the ducts of the gland, with small lesions gradually
building up over time and collecting additional mutations that allow the tumour to
progress to the invasive stage. At this point, the neoplastic cells are able to disrupt the
periglandular basement membrane and migrate into the surrounding stromal tissue 15.
Tumour progression is scored using the Gleason scoring model, wherein the average
and maximum observed tumour grade are evaluated by a pathologist (Figure 1-1)16.

4

Figure 1-1: Schematic diagram of histological progression of Prostate Cancer
using Gleason scoring. In the progression of CaP, (GS-1) normal prostate epithelium
begins to become hyperplastic (GS-2), and progression into a tumour with smooth
round edges (GS-3). As the tumour becomes invasive, the edges of the tumour
becomes ragged and glandular fusion is observed (GS-4). A GS-5 score is made when
the tumour has progressed to the point that the tumour core has necrosed, due to the
need for oxygen and blood flow (Adapted from Epstein et al.16).
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Treatment of Prostate Cancer
Treatment of newly diagnosed prostate cancer typically involves a multi-modal
approach. Tumour removal can be accomplished through radical prostatectomy or
cryosurgery, which entails laparoscopic liquid nitrogen ablation of tumour cells. When
necessary, pelvic lymphadenectomy is performed as well to determine the invasiveness
of the carcinoma. Surgical removal is then usually followed by radiation therapy using
external beam therapy, brachytherapy, and/or proton beam therapy. Traditional
chemotherapeutics and diet modification are also commonly implemented 3.
Treatment of early prostate cancer also typically involves attacking the hormonedependent nature of the early tumour. As it is androgen-dependent for growth, early
success in tumour treatment typically involves hormonal ablatement through the use of
androgen chelating agents, or even as extreme as surgical castration 3,8. However, this
treatment is only effective in the short-term, as the neoplasias that survive then become
hormone-independent, and can metastasize readily throughout the body. At that point,
treatment options are limited, and the cancer is usually terminal. Prostate cancer cells
exhibiting androgen insensitivity still have active androgen receptor (AR) pathways.
Thus, recent work has shown that androgen-independence of the tumour cell has been
shown to be not so much “independence” of androgens per se, but a bypass of the
need for external androgen activation of those same pathways17-19.
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II.

Tumour progression through the epithelial to mesenchymal transition,
angiogenesis, and metastasis
All epithelial tumours that eventually metastasize go through the epithelial to

mesenchymal transition (EMT), wherein the cells develop a phenotype that is no longer
polar, stationary and adherent, and assume a mesenchymal phenotype, which is motile.
This change allows for invasion through the basement membrane into the lymphatic
system, and eventually the bloodstream. The circulating tumour cells can then exit the
bloodstream, and undergo the reverse phenomenon, mesenchymal to epithelial
transition (MET), for clonal growth at the metastatic site9. The EMT transition is marked
by changes in cytoskeletal protein expression and matrix metalloproteinase induction.
Changes in cytoskeletal protein expression
Changes in cytoskeleton protein expression are required for EMT, and
canonically used as a marker of the EMT state of the cancer cell. The early tumour
epithelial cell must suppress e-cadherin and develop a concomitant increase in vimentin
expression. E-cadherin is a transmembrane adherens protein that anchors epithelial
cells to each other in a calcium-dependent manner, and ultimately through interaction
cytoplasmically with β-catenin, to the actin cytoskeleton20-22. Loss of e-cadherin results
in dissociation from the epithelial sheet, and allows for extravasation through the
basement membrane. Likewise, increased expression of vimentin, an intermediate
filament protein that imparts stability to the motile cell, is a canonical marker of the
mesenchymal cell and has been shown to be expressed in poorly differentiated prostate
cancer tumours23-25. Additionally, siRNA inhibition of vimentin expression has been
shown to significantly impact motility of PC-3 prostate cancer cells, although the
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complete mechanism is unknown26. Matrix metalloproteinase enzymes are shown to
cleave the cadherins (E-, N-, and P-), contributing to release of cell-cell contact,
increased cell migration, and loss of epithelial cell polarization27-29.
Angiogenesis of the prostate tumour
A microtumour can develop to the size of 2-3 mm with no requirement for
angiogenesis, as that is the diffusion limit of oxygen and nutrients from surrounding
capillaries. As the tumour grows larger, the core of the tumour necroses (Figure 1-1),
and the surrounding tumour cells adapt to induce angiogenesis. Key proteins induced
in the angiogenic process include vascular endothelial growth factor (VEGF), epidermal
growth factor (EGF), platelet derived growth factor (PDGF), and tumor necrosis factor
alpha (TNF-α) (reviewed in Amankwah et al.30), all of which act to stimulate the
proliferation and migration of endothelial cells in microvasculature formation31.
Metastases in Prostate Cancer
Metastases in CaP typically travel through the lympathic system first to lymph
nodes, then move into the bloodstream and home to bone and brain. Bone metastases
commonly occur in the vertebrae, sternum, pelvic bone, ribs, and femurs32. During the
malignant transformation of prostate cells to metastatic neoplasias, it has been
commonly observed that the cells switch from an epithelial to a osteomimetic, or bonelike expression, with initiated expression of bone matrix noncollagenous proteins such
as osteopontin (OPN), Osteocalcin (OC), and bone sialoproetin (BSP). These proteins
are essential in that OPN assists in osteoclast adhesion, BSP stimulates osteoblast
differentiation, and OC is secreted as a chemoattractant for osteoclast remodeling. This
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change in expression has been postulated to allow for integration of the neoplasia into
the bone.
III.

microRNAs and their role in cancer progression
microRNAs are a class of small RNAs that were described in C. Elegans in

199333, and have since emerged as major regulators of protein levels through
attenuation of translation at the ribosome34-37. microRNAs, or miRs, are 19-22
nucleotide single-stranded RNA sequences that are guided by a protein complex to their
mRNA targets, typically in the 3’-UTR of the mRNA. miRs are present in all animals
and plants, as well as chromalveolata, slime molds, viruses, and yeast38,39. Over 2578
mature microRNAs have been described in humans40,41. microRNA genes are found
throughout the genome, and can be alone, part of another gene within or without exonic
regions, or in a multicistron of multiple microRNAs in tandem.
miR transcription and processing
microRNA transcription is often driven by standard transcription factor activation,
including c-Myc, Sp1, Ets-1, STAT1α, and NF-kB42-44, and most miRs are transcribed by
RNA Polymerase II45. The immature microRNA anneals onto itself in the form of a
hairpin loop, whether transcribed solo, within a gene, or in a polycistron. The hairpin
loop is cleaved from the surrounding message within the nucleus by the RNase III
enzyme Drosha microprocessor complex, which requires the DGCR8 protein as a
cofactor46-48. The resultant 65-100 nt hairpin pre-miRNA is then exported from the
nucleus via Exportin V, which recognizes the double-stranded stem and short single-
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Figure 1-2: Biogenesis of microRNAs. The microRNA is transcribed by Pol II, and
the pre-miRNA is excised from the transcript by Drosha. Export from the nucleus is
active and assisted by Exportin V, and upon exit into the cytoplasm, the pre-miRNA is
bound and cleaved into the mature single-stranded form by the DICER complex. The
RISC complex then guides the mature miR to its target mRNA for translational
suppression and cleavage in some cases. (Adapted from Davis-Dusenbery et al.46)
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stranded overhang created by Drosha cleavage49,50, and further processed into a
mature, 19-21 nucleotide single strand in one of two ways (Figure 1-2). Typical
processing occurs by Dicer, an RNase type III protein, along with its cofactors, but in
some cases, Argonaute 2 (Ago2) itself has been shown to perform cleavage without
need for Dicer46,51. At this point, the selected strand of the pre-miR hairpin is retained in
the RNA-Induced Silencing Complex (RISC) and the passenger strand is ejected from
the complex. Both strands of the immature microRNA can be active in mRNA
translation suppression. Strand selection of the Ago protein that receives the mature
miR has not yet been resolved, although it appears that while some miRs can be
processed and used for repression using all Ago proteins, some miRs are Ago-specific
51.

The RISC is a complex that is primarily composed of Argonaute, an RNA-binding
protein, along with the mature miR strand and several co-factor proteins50,52,53.There are
four Argonaute proteins that are capable of forming the RISC and interacting with
microRNAs for translational repression of targets.
mIR action
The RISC enfolds around the mature microRNA such that the single-stranded
RNA is bound within the protein, with both 5’ and 3’ ends protected from RNase
degradation, and nucleobases 2-9 on the 5’-end of the miR in optimal position for
binding to complementary sequences54. The RISC complex then travels along the
mRNA, the miR binds to the complementary portion, and this
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Figure 1-3: Mechanism of action on mRNA targets of the microRNA-RISC
complex. Most microRNA binding events result in binding to the mRNA target and
translational suppression. However, in the presence of Argonaute 2, which has been
shown to have Slicer activity, a perfect seed-region match (nt 2-9 of the mature
microRNA) to a complementary sequence of the mRNA results in message cleavage
and subsequent degradation.
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binding can cause translational repression, or when the seed-mRNA match is exact and
Ago2 is present, cleavage of the mRNA and subsequent degradation 34,51,55 (Figure 1-3).
Secreted miRs
microRNAs can be secreted from the cell for signaling in a paracrine, endocrine
or autocrine manner. microRNAs can be bound in microvesicles, in protein complexes,
or encapsulated in HDL particles in association with ApoB56-59. The miRs present in
vesicles appear to be miRs secreted for a purpose such as communication, as the
relative abundance levels of miRs found in exosomes of a particular cell type are not
representative of the miR abundance levels found in those cells59. Indeed, cell-cell
communication and resultant changes in protein expression of receiving cells have been
shown in recent reports44.
microRNAs that have been shown to be found in vesicles fuse with the plasma
membrane through the multivesicular bodies (MVBs). They display the same general
characteristics observed in other secreted vesicles, with similar size and shape, as well
as the presence of CD63 antigens when secreted by dendritic, B and T cells59. miRs
contained in vesicles and released into the extracellular environment have been shown
to be resistant to RNase as well as trypsin, indicating that the miRs are neither freefloating in media, nor anchored on the outside of the vesicle.59 miRs have also been
found to be protected from RNase digestion while associated with free protein
complexes, including nucleophosmin 1 (NPM1)57.
miRs as tumour suppressors and oncomiRs
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microRNAs can bind either perfectly or imperfectly to an mRNA target, thus
making it possible for one miR to attenuate the translation of tens to hundreds of
different targets. Additionally, miRs have been shown to impact all aspects of the
proteome, from cell proliferation and apoptosis to mitochondrial and metabolic
processes, to cytoskeleton and secreted products. Thus, microRNAs have recently
been subject to intense scrutiny as modulators of protein levels in cancer, as they are
increasingly being shown to influence carcinogenesis and tumour progression. Since
the target protein level has an inverse relationship to its regulating microRNA, an
overexpressed microRNA is known as an oncomiR, and causes excessive suppression
of its tumour suppressor target mRNA. A tumour suppressor microRNA is one that has
reduced or lost expression, and thus an oncogene that it should regulate is translated
and expressed in an unchecked manner.
IV.

The laboratory’s research objectives and models in use
The objective of our laboratory’s research is to identify potential biomarkers or

therapeutic targets for prostate cancer. We use a combination of in-vitro, in-vivo, and
human prostate cancer samples for validation and verification of our findings.
The P69 cell line is the foundation for a unique progression model for prostate
cancer. The cell line was created from human non-neoplastic prostate epithelial cells
isolated from a transurethral resection of a 63-year old African American male. The
cells were isolated from the extracellular matrix using collagenase and then
immortalized by transfection with the SV40 large T antigen gene60. They retain
epithelial, and specifically basal epithelial cytokeratin markers60 (basal identification
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unpublished data from ZEZ), and are poorly tumorigenic (2/18 mice injected
subcutaneously developed tumours after a long latent period, no metastases).
Metastatic sublines were created by injecting P69 cells subcutaneously into nude
athymic mice. Tumours that developed were excised, analyzed for histopathological
origin, and placed into culture. They were then grown up and subsequently injected
subcutaneously into additional nude athymic mice. This cycle was repeated two
additional times. Each successive injection resulted in faster and more frequent
tumorigenesis61,62. The M2182 cell line was derived from a tumour derived from the
second series of injections, and the M12 cell line, a highly tumorigenic, highly metastatic
cell line63, was derived from the tumour excised from a mouse from the third series of
injections. The M12 cell line produces metastases in lung and diaphragm when injected
subcutaneously, intraperitoneally, and intraprostatically60. Thus, the P69, M2182, and
M12 cell lines represent a progressively tumorigenic model of prostate cancer (Figure 14).
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Figure 1-4: Generation of metastatic sublines from the poorly tumorigenic normal
prostate epithelial SV40T immortalized P69 cell line. Injection of P69 cells resulted
in tumours in only 2 of 18 mice after a long latent period. An excised tumour was then
placed into culture, and the subsequent cells injected into a second nude athymic mice.
This process was repeated one more time, resulting in the highly metastatic and
tumorigenic M12 cell line, which develops tumours in 100% of mice within 12 days, and
produces metastatic sites in the diaphragm and lung.
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Cytogenetic analysis of the M12 cell line revealed deletion of the p-arm and a
portion of the proximal arm of chromosome 19 (19q13.1  19pter), as well as loss of
the Y-chromosome60. Serendipitously, identification of this deletion sparked the
laboratory’s initial interest in microRNAs as chromosome 19 contains a large cluster of
microRNAs known to be crucial to development. Additionally, the miR-17-92 cluster on
chromosome 13 is known to be highly regulated, activated by c-Myc, and dysregulation
has been shown to be associated with cancer42,64,65. Eight of the 21 miRs known to
translationally modulate p21, a cell-cycle inhibitor proten and known effector of multiple
tumour suppressor pathways, are found in the chromosome 13 miRNA cluster37.
Chromosome 19 was reintroduced into the M12 cell lines using microcell-mediated
chromosome transfer (MMCT), and injection of this F6 cell line showed that
reintroduction of chromosome 19 resulted in poor tumorigenesis, loss of metastatic
potential, and increased adhesion of the resultant cells66.
The P69, M12, M2182, and F6 lines are pseudodiploid, which makes the model
appropriate to study early pre-aneuplodic prostatic carcinomas. In contrast, the
canonical prostate cell lines PC-3, DU145, and LnCaP cell lines were derived from
metastatic sites (reviewed in Chapter 3), and are known to have high chromosomal
numbers60,61, an observation commonly made of late stage carcinomas.
Dysregulated miRs identified through the P69-M12 progressive model
Previous work in the laboratory has shown that miR-17-3p, a microRNA found in
the miR-17-92 cluster on chromosome 19, is downregulated in the M12 cells as
compared to the P69 cell line. This loss of expression was shown to have a positive
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effect on vimentin expression through direct targeting by miR-17-3p on vimentin. Thus,
loss of miR-17-3p resulted in an increased level of vimentin, which was then shown to
be reversed upon stable transformation with miR-17-3p, along with reduced
tumorigenicity (Figure 1-5)25.
Recent work has focused on miR-125b as a tumour suppressor miR that was lost
in M12 cells as compared to P69. Analysis of benign and tumour tissue captured
through laser-captured microdissection of prostate biopsies showed a similar pattern.
Restoration of miR-125 through stable transformation resulted in reduced migratory and
invasive potential of M12 cells (Figure 1-6)67. miR-125b has been well characterized as
a suppressor of ERBB2 & 3, receptor tyrosine kinase hormone receptors known to be
upregulated in some carcinomas68-71

18

C

D

Figure 1-5: miR-17-3p directly binds and modulates vimentin mRNA, an
intermediate filament key to the EMT transition. A: Vimentin mRNA expression is
increased through the P69 progression line, and B: miR-17-3p is decreased
concomitantly. C: miR-17-3p directly binds to a portion of the vimentin 3’-UTR, and D:
mutation of the 3’-UTR binding site results in loss of vimentin suppression. From Zhang
et al25.
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Figure 1-6: miR-125b is downregulated in prostate cancer, which allows for
activated transcription of ERBB2/3 and activation of the AKT pathway. A: miR125b was shown to be down-regulated in M12 cells as compared to P69 cells, as well
as in prostate cancer tumour tissue captured via laser capture microdissection. B
Restoration of miR-125b resulted in reduced migratory and invasive capability of M12
cells C: through postulated inhibition of the AKT pathway. From Budd et al67.
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V.

Scope of this thesis

Identification of dysregulated microRNAs in prostate cancer and their target mRNAs
Our laboratory is focused on identifying microRNAs that are modulated in cancer
along with their mRNA targets, thus providing not only a microRNA, but to further
elucidate the modified pathway and its contribution to progression of the prostate
carcinoma. The work in Chapter 3 details a panel-wide analysis of dysregulated miRs
in the M12 cell line, and confirmation of oncomiR or tumour suppressor expression
through additional prostate cell line analysis along with human prostate samples.
Chapters 2, 4, and 5 investigate specific miRs shown to be modulated in prostate
cancer through the multifaceted analysis such as used in Chapter 3. c-KIT, an RTK
growth factor receptor, is identified and confirmed as an additional target of miR-17-3p;
thus loss of that miR results in increased levels of c-KIT and activation of proliferative
pathways. Chapter 4 focused on the identification of miR-9 as an oncomiR, and
evaluates proven targets e-cadherin, NF-kB, and SOCS5 for modulation in the prostate
cancer model. Chapter 5 identifies miR-147b as a novel oncomiR in cancer, and
specifically evaluates modulation and consequent impact on tumour growth and
invasive capabilities. AATF is identified as a novel target for miR-147b through protein
and mRNA expression analysis.
This work culminates in an analysis that, as expected, illustrates that no one
microRNA is responsible for the progression of a prostate tumour. Rather, the
compilation of the work of this laboratory has identified multiple microRNAs that each
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contributes to the progression of the tumour, and their individual contributions result in
an overwhelming activation of proliferative pathways and repression of terminal ones.
Stability of microRNAs in forensically relevant biological fluids
Dr. Zehner’s and my work began with a question of whether microRNAs could be
used for body fluid identification in forensic samples. As a forensic scientist and a
researcher, body fluid identification has long been my passion, and being well familiar
with the limitations of the currently accepted and researched techniques, she and I were
curious as to whether her interest, microRNAs, could be used in a forensic context.
This collaboration began at the cusp of the exploratory literature of microRNAs in the
forensic biology field, and thus our interest in using miRs as a potential molecular
method of body fluid identification must first be tested through an evaluation of the
stability of miRs in forensically relevant body fluids. Thus, while wildly different from the
rest of the thesis, this stability evaluation also holds a place in our research, and
answers some unresolved questions in the forensic science field about the utility of
miRs for forensic science.
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Chapter 2
Identification of c-KIT as a novel target for miR-17-3p in prostate cancer
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Our laboratory uses the previously described SV40T immortalized human
prostate cancer cell line progression model, initiated with P69. The P69 line is
analogous to and derived from normal prostatic tissue and is poorly tumorigenic in nude
athymic mice, whereas the subline M12 is highly tumorigenic and highly metastatic.
This unique model in prostate cancer research permits the identification of additional
players required for the progression of prostate tissue from benign to tumour. Thus,
both microRNAs and their protein targets that are in fact driving the change in
neoplastic potential between the two cell lines can be elucidated.
Previous work had identified vimentin mRNA as differentially expressed between
the P69 and M12 cell lines25 (Figure 2-1a), in correlation with the change in EMT
between the related cell lines and acquired invasive potential of the M12 subline.
Investigation into the source of this differential expression revealed a highly conserved
3’-UTR with a binding site for miR-17-3p in the human vimentin mRNA. Evaluation of
miR-17-3p levels in the P69 to M12 progression model showed a gradual loss of miR17-3p (Figure 2-1b), with a concomitant increase in vimentin expression. Restored
expression of miR-17-3p in the M12 cell line by stable transformation resulted in a fivefold increase in miR-17-3p expression, causing reduced tumour growth in subcutaneous
injection in mice and reversion of vimentin message and protein expression (Figure 21c).
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Zhang et al.

Figure 2-1: miR-17-3p is lost in the P69-M12 progression model, which affects
vimentin expression. A: Vimentin mRNA levels increase through the P69 to M12
progression model. B. The increase in vimentin is inversely correlated to a loss of miR17-3p in this progression. C. Stable reintroduction of miR-17-3p results in suppression
of vimentin (from Zhang et al25).
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As part of the miR-17-92 cluster on chromosome 13q31.3, miR-17 (5p and 3p),
as well as the other members of the cluster (miRs-18a, -19a&b, -20a, and -92a) are all
transcribed by Pol II in the same polycistronic RNA, cleaved to individual precursor
miRs, and exported and processed to mature miRNAs in the cytoplasm 65. Transcription
of the cluster is activated through c-Myc and the protooncogene Pim-142, and thus the
miR-17-92 cluster is commonly described as overexpressed in cancer. miR-17-3p is
not well researched, while the other strand, miR-17-5p, has been well-established as an
oncomiR. Thus, it is postulated that during tumorigenesis, activation of the miR-17-92
cluster results in overexpression of certain members of the cluster, with strand selection
for miR-17-5p and concomitant loss of miR-17-3p. This could result in not only loss of
tumour suppressor protein expression by miR-17-5p, but also loss of regulation of
oncogenes by miR-17-3p.
In an effort to identify additional proteins that may be modulated through the loss
and subsequent re-expression of miR-17-3p in M12 cells, a collaboration was formed
with Dr. Emanuel Petricoin, of George Mason University, who along with Dr. Lance
Liotta, first described the Reverse phase Protein Microarray, or RPMA15. The RPMA is
a method in which a cell or tissue lysate, containing the entire proteome of that sample,
is spotted at a concentration of 250 µM onto glass-backed nitrocellulose slides, and
then fluorescently tagged antibodies are washed across the slides. This allows for rapid
analysis of hundreds of individual samples, with demonstrated use in therapeutic
proteomics72-75. Spotting the same lysate onto hundreds of slides can make for rapid
immunohistochemical analysis of a large set of proteins that could be implicated in
tumorigenesis. RPMA analysis and comparison between the P69, M12, and M12 cells
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+ miR-17-3p identified the phosphorylated version of the V-Kit Hardy-Zuckerman 4
Feline Sarcoma Viral Oncogene Homolog, also known as c-KIT, CD117, and/or Stem
Cell Factor Receptor (SCFR), as differentially phosphorylated between the M12 and
P69 cell lines67. In fact, c-KIT was the most dramatic differentially expressed protein
between the two cell lines, warranting further investigation (Table 2-1).
Interestingly, reintroduction of miR-17-3p to the M12 cell line also resulted in total
ablation of the p-c-KIT signal in the proteomics analysis (Figure 2-2). phospho-c-KIT
levels were undetected in the benign prostatic cell line P69, and highly detectable in the
tumorigenic and metastatic M12 cell line. Reintroduction of miR-17-3p resulted in total
loss of the p-c-KIT signal.
Given these dramatic changes in c-KIT levels between the P69 and M12 cell
lines with complete ablation in the M12 + miR-17-3p transformant, it was important to
determine the mechanism of c-KIT modulation, as well as investigating which signaling
pathway(s) were subject to the tumour suppressor activity of miR-17-3p.
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Table 2-1 – Significant differences in key proteins in M12 versus P69 cell lines as
determined by RPMA proteomic analysis. p = phospho-specific antibody

Protein

Fold Change (M12 to P69)

p-c-KIT

700

p-ErbB3

2

p-ErbB2

1.8

p-Androgen Receptor

1.7

p-BAD

1.7

Caspase 7

1.5

p-PI3 kinase

1.4

p-GSK3A/B

1.2

BCL2

1.2

p-p27

0.7

Cyclin B1

0.6
*adapted from Budd dissertation67
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Figure 2-2: Re-Introduction of miR-17-3p into M12 cells ablates p-c-KIT levels.
RPMA analysis was conducted on 3 sequential passages of each cell line. Serial
dilutions of each replicate were probed for phospho-c-KIT, and expression normalized
against the global protein expression mean.

29

c-KIT is a 145 kDa transmembrane receptor tyrosine kinase, identified
immunologically as CD117. It is typically only expressed in high levels in hematopoietic
stem cells, mast cells, melanocytic cells, germ cells, and interstitial cells of Cajal, and
functions to promote cell proliferation and survival through interaction with its ligand
stem cell factor (SCF)76. SCF can be either membrane-bound for an autocrine function,
or secreted from the cell for a paracrine effect77 . Activation of c-KIT through ligand
binding by SCF induces homodimerization, intermolecular tyrosine phosphorylation, and
immediate internalization and rapid degradation via the ubiquitination pathway77,78.
Upon binding and internalization, c-KIT protein is very slow to recover to previous
levels, on the order of >24 hours78. Levels are also heavily influenced by translational
and transcriptional repression, further confirming a short half-life for the cell-surface
protein78.
The c-KIT gene is located in the white spotting locus 4q11-12, and has also been
associated with piebaldism in both human and mouse77,79. Transcriptional activation is
accomplished through a variety of common transcription factors, including multiple Sp1,
Ets, AP-2, and MyB binding sites80. The signal transduction pathways activated by cKIT include MAPKinase, PI3-Kinase, JAK/STAT, Src, and phospholipase C pathways
(Figure 2-3, reviewed in Reber et al., Lennartsson et al.77,81). As the majority of these
pathways are pro-survival and/or pro-proliferation, activation of c-KIT in neoplasias is
unsurprising, and consequently it is the target of several chemotherapeutic approaches.
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Figure 2-3: c-KIT activation induces signal transduction in a variety of
proliferative pathways (adapted from Reber et al.77)
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Mutation causing a constitutively active c-KIT results in uncontrolled proliferation
and has been found to be a primary tumorigenic cause of gastrointestinal stromal
tumours (GIST)82. This mutation is typically a ligand-independent RTK activity, resulting
in constant stimulation of downstream proliferative pathways.
In normal prostatic tissue, c-KIT expression historically has been found only in
mast cells83, but recent studies have shown increasing c-KIT expression as tumour
progression increases, with c-KIT positive tumours leading to disease relapse and bone
metastasis76,84.
In this study, we evaluated the potential of miR-17-3p as a modulator of c-KIT
expression in a prostate cancer model. Proteomic analyses showed that c-KIT
expression, while absent in the poorly-tumorigenic P69 cell line, was highly expressed
in the M12 cell line, and reintroduction of miR-17-3p to the same cell line resulted in
complete loss of c-KIT signal and reduced tumorigenesis and metastases.
Project Aims:
1. Confirm c-KIT modulation between the P69, M12, and M12 with stably expressed
miR-17-3p cell lines through mRNA and protein expression analysis.
2. Identify miR-17-3p binding sites within the c-KIT message, and determine if they
contribute to message suppression.
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METHODS AND MATERIALS
Cell Culture
Adherent cells were cultured in 75 cm2 flasks using RPMI 1640 supplemented
with L-Glutamine (Caisson Labs, North Logan, UT), 5% fetal bovine serum, 5 µg/mL
insulin, 5 µg/mL transferrin, 5 µg/mL selenium (ITS, Collaborative Research, Bedford,
MA). Gentamycin (0.05 mg/mL) was used to prevent bacterial contamination. M12 cells
previously stably transformed with pSIREN:miR-17-3p vector (Clontech Laboratories,
Inc., Mountain View, CA) were maintained using puromycin25 (100 ng/mL). Cells were
passaged when 50-65% confluent, and maintained for no longer than 20 passages.
Passaging was accomplished by incubating with 0.25% Trypsin-EDTA (Gibco-Life
Technologies, Carlsbad, CA) for 5 minutes at 37°C, after which the trypsin was
inactivated by washing the cells in serum-containing media. The cells were then
pelleted through centrifugation at 1500xg for 5 minutes and either passaged, plated, or
pellets preserved. Cell pellets for analysis were produced by washing the pellet in 10
mL PBS, centrifugation at 1500xg for 5 minutes, removal of the supernatant, and flash
freezing in liquid nitrogen. Pellets were stored at -80°C for at least 24 hours.
RNA Isolation
RNA was isolated from cell pellets using the miRVanaTM RNA isolation method
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA),
eluted in 50 µL of Elution Buffer, and stored at -80°C. RNA concentration was
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad

33

Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (ThermoFisher Scientific, Inc., Waltham, MA).
Messenger RNA Analysis
Messenger RNA was quantified using reverse transcription-quantitative PCR
(RT-qPCR). Reverse transcription was accomplished using the iScript TM cDNA
Synthesis kit (Bio-Rad Laboratories). Briefly, 50 ng of RNA was mixed with 4 µL of the
5X iScript reaction mix, 1 µL of the iScript Reverse Transcriptase, and the volume
brought to 20 µL with nuclease-free water. The reaction mixture was incubated for 5
minutes at 25°C, followed by 30 minutes at 42°C, and heat inactivation for 5 minutes at
85°C. Reactions were stored at -20°C until analysis. The qPCR reactions were
prepared by adding 3 µL of the prepared cDNA, 10 µM primer pairs for the relevant
mRNA target (GAPDH: Forward: 5’-ACCACAGTCCATGCCATCAC; Reverse: 5’TCCACCACCCTGTTGCTGTA. c-KIT: Forward: 5’-ATGAGAGGCGCTCGCGGCGC;
Reverse: 5’-AGCTTGGCAGGATCTCTAAC), 1X FastStart Universal SYBR Green
Master Mix (Roche Diagnostics, Indianapolis, IN), and brought to 20 µL volume with
nuclease-free water. qPCR was conducted in an Applied Biosystems 7300 real-time
PCR instrument (Life Technologies) using the following conditions: 50°C for 2 minutes,
95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for 35
seconds, and 68°C for 35 seconds. Data was analyzed using SDS software v1.3.1 (Life
Technologies), using automatic threshold and baseline settings. Each mRNA evaluated
was analyzed in triplicate using a minimum of three separate cell passage RNA
extractions. GAPDH was used as a normalization control, and relative expression was
calculated using the comparative CT method85.
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Western Blotting
Cultured cell pellets were lysed in 4% sodium dodecyl sulfate (SDS) in
phosphate-buffered saline (PBS) with 1X PhosSTOP phosphatase inhibitor (Roche
Diagnostics) and COMplete protease inhibitor (Roche Diagnostics), followed by
sonication for five minutes at 4°C. Protein concentration was calculated using the Dc
Protein Assay (Bio-Rad Laboratories), and absorbance read at 750 nm on the Smart
SpecTM 3000 Spectrophotometer (Bio-Rad Laboratories).
For western blotting, equal quantities of cell lysate (30-40 µg) were loaded onto a
Novex® 4-12% Tris-Glycine SDS polyacrylamide gel (Life Technologies), under
denaturing conditions using a loading buffer with 2% SDS, 5% β-Mercaptoethanol, 20%
glycerol and 0.004% bromophenol blue in 0.125M Tris-HCl, and electrophoresed in a 25
mM Tris, 190 nM glycine, 0.1% SDS running buffer for approximately 90 minutes at 140
volts. The samples were transferred onto a Trans-Blot® nitrocellulose membrane (BioRad Laboratories) for 90 minutes at 200 mA and 4°C in a 48 mM Tris, 39 mM glycine,
0.04% SDS transfer buffer. Nonspecific binding was prevented by washing the blot for
30 minutes at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.05%
Tween-20 (TBST).

The blot was rinsed briefly in TBST, and incubated overnight (14-

20 hours) at 4°C in primary IgG antibody in 5% BSA in TBST. Primary antibodies used
were 1:1000 α-β-actin (C4) produced in mouse (Santa Cruz Biotechnologies, Inc.,
Santa Cruz, CA) and 1:500 α-CD117 produced in rabbit (Dako, Glostrup, Denmark),.
After incubation in primary antibody, the blot was washed with TBST four times for 5
minutes, followed by incubation in secondary antibody (1:1000 α-mouse IgG-HRP
produced in goat (Santa Cruz Biotechnologies) and/or 1:1000 α-rabbit IgG-HRP
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produced in goat (Cell Signalling Technology, Danvers, MA), for 1 hour at room
temperature. The blot was again washed with TBST four times for 5 minutes, and
luminol reaction developed using the Western Lightning® chemiluminescent reagents
(Perkin Elmer, Boston, MA). Western blots were exposed and bands quantified using
the ODYSSEY® Fc Imaging System (LI-COR Biosciences, Lincoln, NE).
Cloning of 3’-UTR constructs
A 612 base pair portion of the 3’-UTR of c-KIT containing both potential miR-173p binding sites was amplified from a cDNA plasmid containing the c-KIT 3’-UTR (gift
from Dr. Jeff Krystal, Veteran’s Administration Hospital), and inserted into the XbaI
restriction site in the MCS downstream from the luciferase gene in the pmiR-Glo vector
(Promega Corporation, Madison, WI) using standard cloning techniques. This cloning
reaction resulted in not only the desired insert in the correct orientation, but also 2
tandem copies of the 612 bp fragment.
Wild type and mutated fragments of the c-KIT 3’-UTR were synthesized through
Invitrogen for oriented cloning into pmiR-Glo. The Wild type fragments were 63 and 64
nucleotides long (sites 2 and 1, respectively), and mutations at the seed region (Table
2-2) were synthesized as indicated. Failure of these mutations to bind miR-17-3p was
verified through RNAHybrid86,87.
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Table 2-2: c-KIT 3’-UTR fragment constructs. miR-17-3p binding site is highlighted
in yellow, the seed region is highlighted in green, and mutated nucleotides are
highlighted in red.
Clone ID
Site-1 WT

Size
64

Sequence

AATGGATTTGATGCTGTTTGACAAAGTTACTGATTCACTGCATGGCTCCCACAGGAGTGGGAAA

Site-1 Mut

64

AATGGATTTGATGCTGTTTGACAAAGTTACTGATTCGGACAATGGCTCCCACAGGAGTGGGAAA

Site-2 WT

63

GTAGCAGGAAATAAAGTATAGGTTTAGCCTCCTTCGCAGGCATGTCCTGGACACCGGGCCAGT

Site-2 Mut

63

GTAGCAGGAAATAAAGTATAGGTTTAGCCTCCTAGTGAGCGTTGTCCTGGACACCGGGCCAGT
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Transfection & Luciferase Activity Analysis
Transient transfections of the 3’-UTR fragments cloned into a firefly
luciferase/renilla reporter vector were performed using TransIT®-LT1 Transfection
Reagent (Mirus BIO LLC, Madison, WI, USA). Briefly, cells were plated to achieve 50%
density in appropriate serum-containing media after 24 hours (1x105 cells/well for a 6well plate, or 2.5x104 cells/well for a 24-well plate). The cells were allowed to adhere
for 24 hours, rinsed with 0.5 mL PBS, and media replaced (2 mL for 6-well plate, 0.5 mL
for 24-well plate). For 6-well plate transfections, 2.5 µg of the cloned 3’-UTR:vector was
mixed with 250 µL of RPMI media with no serum or additives plus 7.5 µL of TransIT®LT1 reagent at room temperature for 15 minutes. For 24-well plate transfections, 0.5 µg
of the cloned UTR:vector was mixed with 50 µL of RPMI media with no serum or
additives and 2.0 µL of TransIT®-LT1 reagent at room temperature for 15 minutes. The
solution was added dropwise to each well, and gently rocked back and forth. The
transfections were incubated for 24 hours under standard cell culture conditions.
Cell lysis and luciferase assays were conducted using the Dual-Luciferase
Reporter Assay System (Promega Corporation). The transfection media in each well
was suctioned off, wells rinsed in PBS, and 1X Passive Lysis Buffer (Promega
Corporation) (500 µL – 6 well plates; 100 µL – 24 well plates) was pipetted into each
well. The samples were rocked for 15 minutes at room temperature, and the lysate
transferred to 1.5 mL microcentrifuge tubes and frozen at -20°C until analysis.
Luciferase and Renilla measurements were taken in a GloMax® 20/20 luminometer
(Promega Corporation). Lysate (20 µL) was added to a new 1.5 mL microcentrifuge
tube, and 30 µL of firefly Luciferase Assay Reagent II added to the lysate and luciferase
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activity measured at a wavelength of 560 nm. Subsequently, 30 µL of Stop & Glo was
added, the solution mixed, and renilla luciferase activity was measured at the 480 nm
wavelength.
Data Analysis
Statistical analyses were conducted in the Microsoft® Excel software platform,
using the independent Student's t-test, assuming equal variance between the two
groups. Statistical significance was defined as p < 0.05.
RESULTS
Western blot analysis of c-KIT protein in cell lysates corresponded with the
RPMA analysis data, showing that while c-KIT was minimally detectable in P69 cells, it
was highly expressed in the metastatic M12 cell line, and introduction of miR-17-3p
resulted in total loss of the c-KIT protein expression (Figure 2-4). This demonstrates
that the protein levels themselves are dramatically changing, and not just the active
phosphorylated quantity.
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Figure 2-4: c-KIT protein mRNA expression and protein levels are significantly
reduced when miR-17-3p levels are high. A: messenger RNA levels of c-KIT are
significantly reduced in P69 cells as compared to the M12 line (p < 0.0001), with further
reduction when miR-17-3p is overexpressed in M12 cells (p < 0.05). Data is the
average of 3 independent experiments. B: Western blot analysis and C: Densitometry of
c-KIT protein expression in the P69, M12, and M12 overexpressing miR-17-3p. Blot is
representative of 3 independent experiments; quantitation is compiled data from the 3
experiments (p < 0.05 for P69 to M12, and M12 to M12+miR-17-3p c-KIT).
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Review of the major microRNA-Target prediction software platforms (DIANA88,
MiRDB89, TargetMiner90, RNA2291) showed that only RNA22 andTargetMiner included
targeting of miR-17-3p to c-KIT in a list of the top 40 candidate target genes for miR-173p. TargetScan predicted binding, but at a lower confidence level. Analysis of the cKIT 3’-UTR using TargetScan revealed multiple highly conserved potential candidate
sites where miR-17-3p might bind (Figure 2-5)92-94. Analysis of those sites using
RNAHybrid yielded the top two candidates, based on the best binding of the microRNA
seed, with large, equal predicted free energy values (Figure 2-6)86,87.
To validate the predicted binding of miR-17-3p to the c-KIT 3’-UTR, a 612 base
pair portion of the 3’-UTR of c-KIT containing both potential binding sites was amplified
and inserted downstream of the firefly luciferase gene in the Dual-Luciferase miRNA
Target Expression vector pmiR-Glo® (Promega Corporation). The cloning preparation
resulted in not only a pmiR-Glo® vector with a single copy of the c-KIT 3’-UTR, but also
a second clone with two tandem copies inserted downstream of the luciferase gene.
Comparison of luciferase activity (relative to Renilla luciferase activtiy) showed that
expression was suppressed with a single copy of the cloned portion of the 3’-UTR, and
that 2 tandem copies of that portion suppressed activity even further in M12 cells.
Evaluation in the M12 + miR-17-3p overexpressing cell line showed even greater effect,
substantiating that miR-17-3p is directly responsible for at least a portion of suppression
of c-KIT expression (Figure 2-7).
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Figure 2-5: In-silico evaluation of the top two miR-17-3p binding sites in the c-KIT
3’-UTR region show high conservation. Nucleotides 959-1075 of the 3’-UTR region
of c-KIT show two potential binding sites for miR-17-3p. Red and brown fonts outline
entire miR-binding region, and red and brown boxes denote the miR seed-pairing region
wherein canonical miR binding is best. (hsa: homo sapiens ptr: chimpanzee mml:
rhesus monkey oga: bushbaby tbe: tree shrew mmu: mouse laf: elephant eca: horse)
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Figure 2-6: Predicted binding of miR-17-3p to 2 c-KIT 3’-UTR region binding sites.
The two binding sites with highest free energy are within 100 nucelotides of each other.
Green is the sequence of miR-17-3p, and red is the complementary region of the 3’UTR of c-KIT. (Adapted from RNAHybrid86,87).
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Figure 2-7: c-KIT expression is suppressed by miR-17-3p. M12 cells and M12 cells
stably transformed with a vector expressing miR-17-3p were transiently transfected with
a luciferase reporter construct containing a single or double tandem copy of a portion of
the c-KIT 3’-UTR. Firefly luciferase expression is reported normalized to renilla
luciferase activity and relative to empty vector expression. Results are the mean of 3
independent experiments, each performed in triplicate.
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Subcloning efforts to isolate and mutate both miR-17-3p binding sites individually
through synthesized 3’-UTR fragments revealed through luciferase 3’-UTR constructs
that both binding sites have a minor but significant impact on c-KIT expression,
suggesting that the additive effect of the two could allow for significant repression of
translation (Figure 2-8).
c-KIT expression affects many downstream pathways, including the AKT, ERK,
and JAK/STAT pathways. Through RPMA analysis, we found that neither p-AKT, pSTAT3, nor p-ERK were significantly affected by the addition of miR-17-3p into the M12
cell line (Figure 2-9).
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Figure 2-8: Suppression of each binding site in the c-KIT 3’-UTR contributes to
mRNA translation suppression. M12 cells expressing miR-17-3p were transiently
transfected with wild type (WT) or mutated (MUT) sequence of each of the two binding
sites for miR-17-3p within a 612 bp portion of the the c-KIT 3’-UTR. Firefly luciferase
expression is reported normalized to renilla luciferase activity and relative to mutant
expression. Results are the mean of 2 independent experiments, each performed in
triplicate.
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Figure 2-9: miR-17-3p does not significantly affect downstream levels of c-KIT
pathways. RPMA analysis was conducted on 3 sequential passages of each cell line.
Serial dilutions of each replicate were probed for the phosphorylated antibodies shown.
Data is represented as average expression normalized by the global phosphoprotein
mean and relative to M12 cell line expression levels.

47

DISCUSSION
c-KIT is a oncoprotein that is well-characterized in a variety of cancers including
breast, gastrointestinal, non small-cell lung carcinomas, and oral squamous cell
carcinomas82,95-97. While initial reports in prostate cancer were conflicting in their
determination of c-KIT expression, the current literature indicates that c-KIT expression
is found in more aggressive, metastatic prostatic neoplasias, but not in early tumours,
and has some role in promoting establishment of bone metastases 84.
In this report, previous RPMA analysis work that identified c-KIT as a modulated
protein between the P69 and M12 cell lines was confirmed, showing consequent loss of
expression in the M12 cells transformed with a miR-17-3p expression construct67.
Western blot analysis showed that while only slightly detectable in the P69 cell line, cKIT was highly expressed in the M12 cells, and subsequently lost in the M12 cells
overexpressing miR-17-3p. This analysis provided not only confirmation of differences
as seen with RPMA, but also showed that protein levels themselves are changing, and
not just the amount of active, phosphorylated c-KIT protein as indicated by the RPMA
analysis. Interestingly, messenger RNA levels of c-KIT were also modulated by miR17-3p. As miR binding to the 3’-UTR of a target mRNA typically results in translational
repression, and only results in cleavage when the seed pairing is a perfect match and in
complex with Argonaute 234,51,55, mRNA modulation indicates at least one perfectly
matching seed region and cleavage of the message by Argonaute 2.
Subsequently, two strong potential binding sites for miR-17-3p in the 3’-UTR of cKIT were identified, and through reporter luciferase assays determined that:
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1. The 3’-UTR is bound and translation suppressed by miR-17-3p.
2. Comparison of reporter activity using wild type and mutated potential binding
sites showed that both had modest suppressive activity. Thus, we suggest that
the additive effect of the two miR-17-3p binding sites contributes to the overall
suppression of translation for the c-KIT protein in our model cell lines.
There is some concern that even the additive effects of the two identified miR-173p binding sites in the 3’-UTR may not be sufficient to completely ablate protein levels in
the P69 and M12+miR-17-3p cell lines. Further analysis of the c-KIT gene identified two
additional potential binding sites for mIR-17-3p within the c-KIT gene. These potential
sites were not previously identified because they are located within the coding regions
of the message itself, and not the 3’-UTR, which is canonically the location for miRtarget binding. However, there is a growing body of evidence that miRs can bind and
suppress translation of their target mRNAs not only in the 3’-UTR, but also within the 5’UTR and coding regions of the messenger RNA98,99. One example in particular is
interesting and similar to our c-KIT evaluation – miR-34a has been proven to target
Diacylglycerol Kinase ζ in T-cells through binding sites in both the 3’-UTR and the
coding region99.
The binding for the two sites within the cKIT mRNA is particularly strong, and are
the only two potential sites in c-KIT that are stronger in free energy than the two 3’-UTR
sites that were identified and modulated here (Figures 2-10 A&B). Binding site CD-A is
a strong match, with full complementarity in the 3-7 nt seed region of miR-17-3p, and
interestingly, the binding begins at nucleotide 1 in the c-KIT messenger RNA, even prior
to the signal peptide sequence. Binding site CD-B is found in exon 13, which is part of
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CD-A

CD-B

Figure 2-10: Additional potential binding sites for c-KIT can be found in regions
other than the 3’-UTR. CD-A is found at the 5’ end of the message, starting at
nucleotide 1. CD-B is found in exon 13 of the c-KIT message. Green is the sequence
of miR-17-3p, and red is the complementary region of the c-KIT mRNA. (Adapted from
RNAHybrid86,87).
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the intracellular domain of the protein77 and is found in 3 of the 6 alternative splicing
forms of the c-KIT protein.
As an important primary signal transduction initiator, c-KIT is naturally heavily
regulated, not only at the transcriptional level, but growing evidence indicates that
multiple microRNAs are important for regulation at the translational level. miR-221 has
been shown to regulate c-KIT levels in erythroleukemic cells100, but was within the
normal range in our evaluations and thus was not pursued. MiR-34a has recently been
shown to directly target c-KIT levels in a colorectal cancer cell line, with two binding
sites in the 3’-UTR101. miR-34a was evaluated by other work in the laboratory and
shown to be an oncomiR in both the cell line progression model as well as in patient
LCM analyses67. An interesting observation from the compilation of unpublished data
show that while miR-34a is dramatically upregulated in the P69 cells as compared to the
M12, this seems to have no effect on the c-KIT levels. It may be that miR-34a is
involved in regulation of other tumour suppressor mRNAs, and the c-KIT message is not
efficiently targeted in the prostate cancer system.
A particularly interesting microRNA:c-KIT interaction case is that of miR-494.
This miR was proven to downregulate c-KIT expression levels in gastrointestinal stromal
tumour cells (GIST) through multiple binding targets within the c-KIT 3’-UTR82.
Proliferation was affected via the c-KIT downstream pathways. Interestingly, in the
panel analysis (Chapter 3), miR-494 was undetected in both the P69 and M12 cell lines
by RT-qPCR analyses, and thus is not a likely player in c-KIT modulation in prostate
cancer. Thus, this discovery of miR-17-3p’s regulation of c-KIT presents an interesting
parallel case to the miR-494 in the GIST report, wherein different microRNAs through
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tissue-specific expression fulfill a similar tumour suppressing role. Loss of expression in
their respective tissues results in uncontrolled growth through loss of suppression of an
oncogene.
c-KIT positive cancers from a variety of origins are commonly treated with
Imatinib and other growth factor receptor chemotherapeutics. Imatinib directly blocks cKIT activation at the ATP-binding pocket82. However, constitutively activated mutations
for c-KIT are well known, and blocking therapeutics are not effective for those mutants.
A method that blocks translation of the mutated protein could be a very effective
therapeutic tool. Given that c-KIT has been so well-established as a rapidly cycling
protein78, its translational repression could have an almost immediate effect on the
reception of growth signals and downstream proliferative signaling to tumour cells
resulting in the ultimate attenuation of growth and cell cycling, as was shown in the
study evaluating miR-494 inhibition82. A combination of miRs shown to target the c-KIT
mRNA, but without additional known pro-growth effects (such as miR-34a) could
potentially work to attenuate the growth and chemotaxis of neoplasias through
suppression of the initiator of those signal transduction processes.
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Chapter 3:
Identification of modulated microRNAs through a sequential analysis of prostate
cancer cell lines and patient samples
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Most researchers approach miR discovery in a single approach. Some have a
protein or pathway that encompasses their entire research, while others are interested
in identifying microRNAs on a global scale that affect diseases and conditions such as
cancer. While our laboratory initially began working on microRNAs through the
discovery of miR-17-3p as an attenuator of vimentin protein levels, we have continued
to work in microRNA discovery in prostate cancer in a search for additional microRNAs
that could be serving as oncomiRs or tumour suppressors. And while we begin this
research on a global scale, we are interested in not only identifying those miRs, but
determining their mechanism of action through target mRNA identification and
connection with a signaling pathway that progresses the carcinoma.
The previously described progression cell lines P69 and M12 are a unique model
for prostate cancer, in that P69, having been immortalized from a human non-neoplastic
prostate epithelium section60,61, is poorly tumorigenic and non-metastatic in nature. In
contrast, the M12 cell line, which was derived from 3 sequential injections into nude
athymic mice, is highly tumorigenic and highly metastatic. This set of cell lines serves
as an excellent model for prostate cancer research, in that the M12 cells are derived
from the P69 cells and therefore share a common basic genetic complement.
As the M12 and P69 cell lines are not readily available to other researchers,
several cell lines are commonly used as models for prostate cancer (Table 3-1). The
PC3 cell line is a line that was derived from a vertebral bone metastasis in a 62-year old
male, and is androgen-insensitive102. It no longer expresses PSA or the androgen
receptor103 and is highly tumorigenic and metastatic, and thus is commonly used to
evaluate prostate cancer therapeutic targets for advanced cancers. The other canonical
54

prostate cell line is the Dunnings-145 (DU-145), which was derived from the brain of a
69-year old white male with both CaP and lymphocytic leukemia, is only moderately
metastatic but also androgen-insensitive103,104. DU145, like PC3, also does not express
PSA or the androgen receptor. A non-tumorigenic cell line known as BPH-01 is a
SV40T immortalized line derived from a human benign prostatic hypertrophic (BPH)
biopsy23,105. While there is some disagreement among researchers as to whether BPH
always ultimately develops into neoplasia in-vivo, in-vitro, the BPH-01 cell line has only
been shown to form adenocarcinomas when injected with carcinoma-associated
fibroblasts24. WMPY-1 is a stromal myofibroblast line that is sometimes referred to in
CaP research, but since it is not endothelial in nature, it is not as relevant as the other
lines are to the progression of CaP105.
The only publicly available progression model for prostate cancer is the LNCaP series
of cell lines. The original LNCaP cell line was derived in 1977 from a metastatic
supraclavicular lymph node in a 50-year-old male106,107. It is unique from the other cell
line models in that tumour development is androgen-sensitive. The C4 and C5 sublines
were derived through the injection of the LNCaP cells into male nude athymic mice,
followed by subsequent castration after 8 weeks108. Tumours that were maintained
after castration exhibited hormone independence, and thus formed the basis of the C4
and C5 sublines. Subsequent reinjection of the C4 cells into nude athymic mice in
combination with human marrow stromal (MS) fibroblasts generated an even more
androgen-refractory cell line designated LNCaP-C4-2108. Interestingly, the C4, C5, and
C4-2 sublines have lost the Y-chromosome, continue to express PSA and have a lower
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Table 3-1: Cell line models used in prostate cancer research
Cell Line
Metastatic Potential
Androgen Sensitivity
Stand-Alone Cell Lines
PC3
High
No
DU-145
Moderate
No
BPH-01
None – benign hyperplastic epithelium
Progressive Models
P69
M12

Negligible
High

No
No

LNCaP
LNCaP-C4/C5
LNCaP-C4-2

Very Low
Low
Moderate

yes
Moderate
No
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level of the androgen receptor, all trademarks of hormone-refractory CaP in humans109.
Thus, the LNCaP progression set of cell lines is a well-established progression model
for studying prostate cancer. Additionally, the series is an accurate model for metastatic
potential, as the sublines form osteoblastic lesions32, the canonical mechanism for
human prostate cancer metastases to bone, in contrast to the PC3 and DU-145 lines,
which form osteolytic lesions similar to the bone lesions seen in breast and other
cancers105.
While each of the described cell lines can act as good models for prostate cancer, any
one cell line alone should not be used as a discovery tool for identifying novel
modulated species, including microRNAs. Any balanced discovery should include not
only the easily obtainable cell lines, but also patient samples. In this way, confirmation
of the preliminary results obtained from the cell-line work can be confirmed as also
occurring in the prostate cancer patient, and thus will be more relevant not only in
identifying new markers, but also in developing new therapeutics against prostate
cancer. In this study, we proposed to identify microRNAs that have been modulated in
prostate cancer through a progressive, sequential analysis that begins at the global
miRNA level, proceeds through single-miR confirmatory analysis, followed by evaluation
of miR expression in multiple additional prostate cancer cell lines and finally analysis of
modulated microRNAs through laser-capture microdissection (LCM) of benign, stromal,
and tumour tissue from human patient biopsies.
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Project Aims:
1. Identify miRs that are dysregulated in prostate cancer through RT-qPCR analysis of
the P69 and M12 cell lines of a human panel of over 700 miRNAs. This will serve to
identify microRNAs as potential oncomiRs when overexpressed in M12 vs. P69, and
as potential tumour suppressors when lost in M12 vs. P69.
2. Confirm miRs identified in Aim 1 through single-miR RT-qPCR analysis in the entire
P69 cell line progression model. Evaluate any differences between results seen with
panels as compared to the single-miR analysis.
3. Evaluate those modulated miRs that continue to act as oncomiRs and tumour
suppressors through analysis of additional prostate cell lines. This will serve to
narrow the field to those miRs that are more indicative of CaP through gain or loss of
expression.
4. Using CaP patient biopsies, perform laser-capture microdissection in order to
separate benign from tumour tissue within the same biopsy slice, and compare miR
expression between benign and tumour, thus confirming (or eliminating) the
proposed miRs as modulated in prostate carcinomas.

METHODS & MATERIALS
Cell Culture
P69, LNCaP and sublines, BPH-01, PC-3, and DU-145 cells were previously cultured
and pellets stored at -80°C until RNA isolation. Adherent M12 cells were cultured in 75
cm2 flasks using RPMI 1640 supplemented with L-Glutamine (Caisson Labs, North
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Logan, UT), 5% fetal bovine serum, 5 µg/mL insulin, 5 µg/mL transferrin, 5 µg/mL
selenium (ITS, Collaborative Research, Bedford, MA). Gentamycin (0.05 mg/mL) was
used to prevent bacterial contamination. Cells were passaged when 50-65% confluent,
and maintained for no longer than 20 passages. Passaging was accomplished by
incubating with 0.25% Trypsin-EDTA (Gibco-Life Technologies, Carlsbad, CA) for 5
minutes at 37°C, after which the trypsin was inactivated by washing the cells in serumcontaining media. The cells were then pelleted through centrifugation at 1500xg for 5
minutes and either passaged, plated, or pellets preserved. Cell pellets for analysis were
produced by washing the pellet in PBS, centrifugation at 1500xg for 5 minutes, removal
of the supernatant, and flash freezing in liquid nitrogen. Pellets were stored at -20°C or
-80°C for at least 24 hours.
RNA Isolation
RNA was isolated from cell pellets using the miRVanaTM RNA isolation method
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA),
eluted in 50 µL of Elution Buffer, and stored at -80°C. RNA concentration was
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad
Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (ThermoFisher Scientific, Inc., Waltham, MA).
Laser-Capture Microdissection
Frozen radical prostatectomy samples were obtained from VCU’s Tissue and
Data Acquisition and Analysis Core, which obtained all samples following approved
institutional review board (IRB) protocols. Each sample was reviewed and scored by a
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board certified pathologist with expertise in prostate cancer diagnosis. 8 μm tissue
slices from the biopsy cores were placed on uncharged glass slides, and stained with
hematoxylin and eosin (H&E) using a standard protocol. Laser capture microdissection
(LCM) was performed using the Arcturus Veritas™ laser capture microdissection
system (Life Technologies). Each tissue type (benign, stroma, venous, tumour) was
separately captured onto CapSure® Macro LCM caps (LifeTechnologies). At least ten
slides were captured for each patient included in the study.
RNA extraction of LCM samples
Total RNA was isolated from LCM caps using the ARCTURUS® PicoPure® RNA
Isolation Kit (Life Technologies), following the manufacturers protocol. Briefly, the LCM
caps were incubated for 30 minutes at 42°C in 50μl of extraction buffer. This extract
was then stored at -20°C until similar cell extracts from successive slides were pooled
into a single tube and mixed with 1 volume of 70% ethanol. The precipitated RNA
solution was loaded onto a MiraCol™ column, centrifuged, washed, and total RNA
eluted in 11 µL. RNA quality and quantity were estimated using an Agilent RNA 6000
Pico chip with the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) using the
manufacturer’s recommendations.
Locked-Nucleic Acid miR Panel Analysis
M12 and P69 RNA (50 ng) were subjected to the miRCURY LNA™ Universal RT
microRNA PCR reaction (Exiqon A/S, Denmark) according to the manufacturer’s
recommended protocol. Briefly, 4 µL of 5X Reaction buffer and 2 µL of reverse
transcriptase enzyme mix were combined with appropriately diluted RNA and brought to
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20 µL volume with RNase-free H2O. The RNA was reverse transcribed for 60 minutes
at 42°C, followed by heat inactivation for 5 minutes at 95°C. The cDNA was diluted and
aliquotted across Exiqon miRCURY LNA™ Universal RT microRNA PCR Panels I and II
(Verson 2.M) 384-well plates according to protocol, and qPCR was undertaken in an
Applied Biosystems 7900HT fast real-time PCR instrument (Life Technologies,
Carlsbad, CA) using recommended cycling conditions. Threshold and baseline settings
were set according to protocol recommendations. The data was corrected for interplate
variability using on-plate calibrators, and normalized against the global mean using
Exiqon GenEx software. Expression changes were calculated in Microsoft Excel® using
the 2Δ ΔCT method and recorded as M12 expression relative to P69.
RT-qPCR (Exiqon)
Single-miR RT-qPCR analysis was conducted using the LNA platform as well.
RNA (40 or 50 ng (LCM and cell lines, respectively)) was reverse transcribed using the
miRCURY LNA™ Universal reverse transcription reaction as described for the Panel
analysis. The cDNA was diluted 1:10 and qPCR mix prepared by adding 5 µL of 2X
Sybr® Green PCR master mix (Exiqon A/S), 1 µL of appropriate primer mix, and 4 µL of
diluted cDNA. qPCR was undertaken in an Applied Biosystems 7300 real-time PCR
instrument (Life Technologies) using recommended cycling conditions. Data was
analyzed using SDS software v1.3.1 (Life Technologies). Threshhold and baseline
settings were set according to protocol recommendations, with baseline correction
between cycles 3 and 12 and an automatic threshold. Each miR was analyzed against
a cell line with a minimum of one biological and three technical replicates.
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RESULTS
Microarray Panel Analysis of M12 and P69 cell lines
Locked-nucleic acid (LNA) RT-qPCR panel analysis of the M12 versus the P69
cell line was the starting point in a search for microRNAs that are truly modulated, not
only in cell-line models, but also in human tumours. Analysis of both Panels 1 and 2
allowed for analysis of known human miRs as of 2011. Out of 736 microRNAs assayed,
231 were found to be oncomiRs (≥2 fold increase in M12 vs. P69 cell lines), 150 were
found to be tumour suppressors (≤.5 fold decrease in M12 vs. P69 cell lines), with the
remaining microRNAs within the normal range (Figure 3-1). Even though the majority of
microRNAs remained within the normal range, this still left many potential tumour
suppressors and oncomiRs to evaluate (Tables 3-2a and b, respectively).
The choice of which microRNAs to investigate further was accomplished through
an evaluation of not only the expression level difference between P69 and M12, but also
initial literature reviews and analysis of potential targets using microRNA-target
databases including TargetScan, DIANA, and miRDB86-89,92,93,110. Literature searches
were conducted in order to determine whether the microRNAs in question had been
previously identified as modulated in prostate or any other neoplasias. The microRNAs
that were selected for further examination comprised the spectrum of both gain and loss
of expression (Table 3-3). While most selected miRs have some demonstrated
evidence promoting carcinoma progression, whether in the form of proven targets or
previous literature in other neoplasias, in some cases, the expression level difference
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Modulated microRNAs via Array Analysis
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Figure 3-1: Analysis of microRNA expression (fold difference in M12 vs. P69 cell
lines). Cultured cells were pelleted, RNA isolated, and subjected to Exiqon miRCURY
LNA™ microRNA system Human panels I and II (version 2.M). Panel I was performed
in duplicate using 20 and 50 ng of RNA; Panel II was performed once, using 50 ng of
RNA. Data was normalized using the global mean, and fold difference calculated.
Values greater than 1 represent higher expression in M12 as compared to the P69 cell
line.
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Table 3-2a: Tumour suppressor microRNAs identified through miRcury RT-qPCR
panel analysis of M12 vs P69 cell lines panels I and II (Version 2.M). Data is sorted
by expression level, and values are fold expression difference in M12 from P69.
Expression
Difference
hsa-miR-548m
0.002
hsa-miR-127-3p
0.002
hsa-miR-411
0.005
hsa-miR-138-1*
0.005
hsa-miR-891b
0.007
hsa-miRPlus-C1089
0.009
hsa-miR-1248
0.017
hsa-miR-299-5p
0.020
hsa-miR-379
0.020
hsa-miR-889
0.025
hsa-miR-548a-5p
0.028
hsa-miR-323-3p
0.031
hsa-miRPlus-D1061
0.036
hsa-miR-34b*
0.037
hsa-miR-487b
0.039
hsa-miR-1238
0.039
hsa-miR-409-3p
0.042
hsa-miR-135b
0.043
hsa-miR-614
0.043
hsa-miR-504
0.044
hsa-miR-1914*
0.045
hsa-miR-520d-3p
0.047
hsa-miR-382
0.048
hsa-miR-1185
0.050
hsa-miR-579
0.051
hsa-miR-659
0.051
hsa-miR-136
0.055
hsa-miR-452*
0.057
hsa-miR-377
0.058
hsa-miR-490-5p
0.059
hsa-miR-936
0.064
hsa-miR-362-3p
0.072
hsa-miR-616
0.080
hsa-miR-432
0.085
hsa-miR-619
0.086
microRNA

Expression
Difference
hsa-miR-135b*
0.146
hsa-miR-132*
0.155
hsa-miR-520a-5p
0.156
hsa-miR-29c*
0.158
hsa-miR-514
0.160
hsa-miR-489
0.161
hsa-miR-145*
0.162
hsa-miR-342-5p
0.165
hsa-miR-23b*
0.169
hsa-miR-556-3p
0.173
hsa-miR-23a*
0.178
hsa-miR-1265
0.187
hsa-miR-148a*
0.189
hsa-miR-143*
0.191
hsa-miR-1267
0.193
hsa-miR-376a*
0.198
hsa-miR-105*
0.199
hsa-miR-1260
0.210
hsa-miR-27a
0.210
hsa-miR-125b-1*
0.212
hsa-miR-380
0.212
hsa-miR-369-5p
0.214
hsa-miR-572
0.215
hsa-miR-100
0.222
hsa-miR-1206
0.225
hsa-miR-19b-2*
0.230
hsa-miR-138-2*
0.232
hsa-miR-598
0.234
hsa-miR-376c
0.235
hsa-miR-31
0.237
hsa-miR-376b
0.241
hsa-miR-1258
0.242
hsa-miR-543
0.256
hsa-miR-191
0.258
hsa-miR-432*
0.267
microRNA
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Expression
Difference
hsa-miR-500
0.319
hsa-miR-2113
0.320
hsa-miR-1227
0.329
hsa-miR-425*
0.333
hsa-miR-146b-5p
0.334
hsa-miR-140-3p
0.338
hsa-miR-127-5p
0.344
hsa-miR-1181
0.349
hsa-miR-587
0.353
hsa-miR-379*
0.358
hsa-miR-1182
0.359
hsa-miR-876-3p
0.365
hsa-miR-296-3p
0.370
hsa-let-7a-2*
0.371
hsa-miR-603
0.372
hsa-miR-411*
0.374
hsa-miR-144
0.374
hsa-miR-1538
0.378
hsa-miR-323-5p
0.382
hsa-miR-758
0.386
hsa-miR-770-5p
0.392
hsa-miR-15b
0.392
hsa-miR-27b
0.395
SNORD38B
0.398
hsa-miR-1270
0.400
hsa-miR-339-5p
0.403
hsa-miR-654-5p
0.404
hsa-miR-19b
0.405
hsa-miR-630
0.408
hsa-miR-449b*
0.413
hsa-miR-1256
0.415
hsa-miR-378*
0.416
hsa-miR-212
0.428
hsa-miR-142-5p
0.431
hsa-miR-302d*
0.446
microRNA

hsa-miR-509-3p
hsa-miR-1237
hsa-miR-541*
hsa-miR-1179
hsa-miR-1236
hsa-miR-640
hsa-miR-135a
hsa-miR-888*
hsa-miR-342-3p
hsa-miR-588
hsa-miR-527
hsa-miR-141*
hsa-miR-196b*
hsa-miR-125b
hsa-miR-516b*

0.091
0.095
0.096
0.098
0.100
0.105
0.122
0.124
0.127
0.130
0.132
0.135
0.137
0.145
0.146

hsa-miR-181a-2*
hsa-miR-302e
hsa-miR-448
hsa-miR-376a
hsa-miR-1245
hsa-miR-493*
hsa-miR-649
hsa-miR-924
hsa-miR-191*
hsa-miR-875-3p
hsa-miR-218-1*
hsa-miR-526b*
hsa-miR-138
hsa-miR-21
hsa-miR-1913
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0.267
0.267
0.272
0.273
0.275
0.275
0.276
0.278
0.291
0.305
0.306
0.306
0.310
0.312
0.316

hsa-miR-100*
hsa-miR-555
hsa-miR-23b
hsa-miR-146a
hsa-miR-769-3p
hsa-miR-125a-3p
hsa-miR-1253
hsa-miR-34c-5p
hsa-miR-224*
hsa-miR-591
hsa-miR-450b-5p
hsa-miR-636
hsa-miR-720
hsa-miR-1914
hsa-miR-203

0.448
0.454
0.455
0.459
0.460
0.469
0.471
0.472
0.475
0.479
0.487
0.489
0.490
0.492
0.493

Table 3-2b: OncomiR microRNAs identified through miRcury microarray analysis
of M12 vs P69 cell lines panels I and II (Version 2.M). Data is sorted by expression
level, and values are fold expression difference in M12 from P69.
Expression
Difference
hsa-miRPlus2.003
A1027
hsa-miR-126
2.004
hsa-miR-34c-3p
2.006
hsa-miR-515-3p
2.007
hsa-miR-621
2.012
hsa-miR-34a*
2.015
hsa-miR-22
2.026
hsa-miR-365
2.042
hsa-miR-491-5p
2.071
hsa-miR-96*
2.084
hsa-miR-1264
2.092
hsa-miR-141
2.093
hsa-miR-589
2.094
hsa-miR-26b
2.105
hsa-miR-187*
2.157
hsa-miR-330-3p
2.168
hsa-miR-32
2.175
hsa-miR-885-3p
2.211
hsa-miR-346
2.219
hsa-miR-28-3p
2.227
hsa-miR-30a*
2.277
hsa-miR-668
2.285
hsa-miR-628-3p
2.295
hsa-miR-1205
2.307
hsa-miR-1296
2.322
hsa-miR-30e
2.327
hsa-miR-200b*
2.340
hsa-miR-125b-2*
2.352
hsa-miR-526b
2.391
hsa-miR-502-5p
2.396
hsa-miR-137
2.417
hsa-miR-214
2.435
hsa-miR-223
2.437
hsa-miR-744
2.443

Expression
Difference
hsa-miR-200c*
3.487

Expression
Difference
hsa-miR-486-5p
9.078

hsa-miR-188-5p
hsa-miR-642
hsa-miR-326
hsa-miR-490-3p
hsa-miR-193b*
hsa-miR-450a
hsa-miR-181c
hsa-miR-208b
hsa-miR-628-5p
hsa-miR-154*
hsa-miR-7-1*
hsa-miR-942
hsa-miR-187
hsa-miR-135a*
hsa-miR-595
hsa-miR-1244
hsa-miR-558
hsa-miR-647
hsa-miR-943
hsa-miR-34a
hsa-let-7d
hsa-miR-429
hsa-miR-675*
hsa-miR-548k
hsa-miR-370
hsa-miR-519e
hsa-miR-520f
hsa-miR-130a
hsa-miR-580
hsa-miR-548i
hsa-miR-890
hsa-miR-146a*
hsa-miR-583

3.557
3.597
3.606
3.612
3.617
3.620
3.650
3.741
3.746
3.751
3.787
3.830
3.830
3.855
3.858
3.885
3.986
4.044
4.137
4.183
4.191
4.224
4.326
4.433
4.444
4.471
4.509
4.531
4.630
4.639
4.692
4.810
5.012

hsa-miR-325
hsa-miR-7
hsa-miR-210
hsa-miR-33b*
hsa-miR-518e

hsa-miR-188-3p
hsa-miR-222*
hsa-miR-518b
hsa-miR-548o
hsa-miR-124

5.021
5.023
5.143
5.164
5.174

hsa-miR-570
hsa-miR-195*
hsa-miR-933
hsa-miR-663b
hsa-miR-337-5p
hsa-miR-551a
hsa-miR-592
hsa-miR-513c
hsa-miR-211
hsa-miR-299-3p
hsa-miR-623
hsa-miR-508-3p
hsa-miR-19b-1*
hsa-miR-517*
hsa-miR-767-3p
hsa-miR-363*
hsa-miR-662
hsa-miR-520b
hsa-miR-196a
hsa-miR-620
hsa-miR-518c*
hsa-miR-3180-3p
hsa-miR-562
hsa-miR-767-5p
hsa-miR-501-3p
hsa-miR-486-3p
hsa-miR-371-5p
hsa-miR-106a*
hsa-miR-338-5p
hsa-miR-33b
hsa-miR-616*
hsa-miR-374b*
hsa-miRPlusA1031
hsa-miR-1269
hsa-miR-372
hsa-miR-557
hsa-miR-512-5p
hsa-miR-202

microRNA

2.483
2.490
2.497
2.499
2.514

microRNA
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microRNA

9.152
9.307
9.341
9.506
9.977
10.377
10.486
10.656
10.954
11.371
11.895
12.437
12.583
12.739
12.925
13.280
13.298
13.474
13.480
13.515
13.620
13.753
15.051
15.266
15.480
16.750
16.886
17.100
17.177
17.468
17.628
17.749
17.818
17.957
18.745
18.817
19.327
19.695

hsa-miR-1249
hsa-miR-339-3p

2.515
2.528

hsa-miR-885-5p
hsa-miR-146b-3p

5.175
5.355

hsa-miR-760
hsa-miR-30d
hsa-miR-1911*
hsa-miR-605
hsa-miR-148b
hsa-miR-877*
hsa-miR-200a
hsa-miR-421
hsa-miR-499-5p
hsa-miR-1263
hsa-miR-26a-1*
hsa-miR-25*
hsa-miR-564
hsa-miR-545
hsa-miR-22*
hsa-miR-548d-5p
hsa-miR-891a
hsa-miR-26a-2*
hsa-let-7c
hsa-miR-200a*
hsa-miR-30c-2*
hsa-miR-184
hsa-miR-1271
hsa-miR-302a
hsa-miR-149*
hsa-miR-552
hsa-miR-510
hsa-miR-10a
hsa-miR-130b
hsa-miR-96
hsa-miR-608
hsa-miR-485-3p
hsa-miR-615-5p
hsa-miR-149

2.529
2.555
2.561
2.583
2.601
2.603
2.655
2.664
2.731
2.741
2.751
2.777
2.805
2.807
2.811
2.836
2.840
2.880
2.932
2.943
3.050
3.077
3.082
3.167
3.175
3.302
3.344
3.349
3.361
3.388
3.404
3.414
3.421
3.432

hsa-miR-600
hsa-miR-597
hsa-miR-15b*
hsa-miR-381
hsa-miR-99a
hsa-miR-223*
hsa-miR-634
hsa-miR-518a-3p
hsa-miR-596
hsa-miR-30c-1*
hsa-miR-516a-5p
hsa-miR-335*
hsa-miR-554
hsa-miR-150
hsa-miR-521
hsa-miR-615-3p
hsa-miR-551b*
hsa-miR-199a-3p
hsa-miR-10a*
hsa-miR-497
hsa-miR-9
hsa-miR-516b
hsa-miR-525-3p
hsa-miR-541
hsa-miR-139-5p
hsa-miR-129-3p
hsa-miR-362-5p
hsa-miR-217
hsa-miR-888
hsa-miR-301b
hsa-miR-1224-3p
hsa-miR-519a
hsa-miR-338-3p
hsa-miR-198

5.403
5.554
5.574
5.729
5.742
5.753
5.801
5.860
5.881
5.921
6.019
6.032
6.091
6.103
6.140
6.170
6.242
6.426
6.566
6.572
6.676
6.816
6.817
7.187
7.456
7.465
7.488
7.616
7.620
7.815
7.950
8.064
8.159
8.234

hsa-miR-302c
hsa-miR-130b*
hsa-miR-1255b

3.435
3.448
3.461

hsa-miR-610
hsa-miR-517a
hsa-miR-10b

8.235
8.245
8.885
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hsa-miR-18b*
hsa-miRPlusD1033
hsa-miR-675b
hsa-miR-873
hsa-miR-1
hsa-miR-412
hsa-miR-491-3p
hsa-miR-498
hsa-miR-937
hsa-miR-451
hsa-miR-520d-5p
hsa-miR-556-5p
hsa-miR-147
hsa-miR-92b*
hsa-miR-515-5p
hsa-miR-517c
hsa-miR-373*
hsa-miR-524-3p
hsa-miR-454*
hsa-miR-133a
hsa-miR-133b
hsa-miR-181c*
hsa-miR-373
hsa-miR-518f
hsa-miR-921
hsa-miR-548l
hsa-miR-375
hsa-miR-143
hsa-miR-631
hsa-miR-153
hsa-miR-105
hsa-miR-622
hsa-miR-122
hsa-miR-147b
hsa-miR-551b
hsa-miRPlusC1076

20.163
21.296
21.361
21.467
23.538
23.833
24.610
25.427
26.513
27.084
27.591
27.696
27.998
28.949
30.258
31.942
34.484
34.725
35.910
37.907
38.930
42.935
45.111
47.556
69.187
76.180
81.495
83.063
85.097
100.736
131.645
147.739
198.567
201.357
264.961
1046.216

Table 3-3: microRNAs selected for further analysis

microRNA

Expression
difference
(M12 vs. P69)

Proven
Targets

Reported in cancer:

9

6.68

CDH1, REST,
CDKN1A, BCL6,
FOXO1, NF-kB1,
ETS-1, CD34,

144

0.374

PLAG1, FGA, FGB

133a

37.91

133b

38.93

146a

0.459

---

147b

201.4

199a-3p

6.43

--MAPK8, MET,
CD44, MAPK1,
AKT1, MET

221

0.783

CDKN1B, c-KIT,
CDKN1C, DDIT4,
p27, ZEB2, TBK1

299-3p
299-5p

11.37
0.02

--OPN

147

27.9

VEGFA

488

0.526

AR

622

147.7

ING1, K-Ras

127-3p

0.002

MAPK4

127-5p

0.344

MMP13

FSCN1, TAGLN2,
GSTP1, COL1A1,
LASP1
FSCN1, PTBP2,
ERG, HCN2, MET
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OncomiR in glioblastoma, lung, hepatocellular,
prostate, gastric, bladder, mesothelioma
Tumour suppressor in ovarian
OncomiR in lung, prostate, esophageal,
nasopharyngeal
Tumour suppressor in bladder, bone, colorectal
Tumour suppressor in ovarian, colorectal,
breast, bone, bladder
Tumour suppressor in bladder, uterine, gastric,
prostate
OncomiR in bone, liver, ovarian, prostate
SNP mutation confers oncomiR in breast,
colorectal, ALL, pancreatic
Tumour suppressor in lung
Tumour suppressor in rectal
OncomiR in colon, gastric, biliary
Tumour suprressor in testicular, bladder,
endometrial, bone, liver
OncomiR in breast, melanoma, pancreatic,
glioblastoma multiforme, AML, prostate, cervical,
ALL
Tumour suppressor in gastric
--Tumour suppressor in breast
OncomiR in liver, lung, gastric, squamous cell
carcinoma of the tongue
Tumour suppressor in breast
none
OncomiR in colorectal
Tumour suppressor in gastric
Tumour suppressor in gastric, B-cell nonHodgkins lymphoma, renal, bone
OncomiR in thyroid, cervical
Tumour suppressor in hepatocellular, colon

was so compelling that miRs were chosen without any known targets or previous
association with cancer.
Analysis of selected miRs using prostate cell lines
The next phase of miR selection was undertaken through single-miR RT-qPCR
analysis of the subset of miRs selected for further investigation (Table 3-3). Through
this work, we hoped to accomplish a two-fold goal: first of all, to confirm the miRcury
microarray data through single-miR analysis of RNA from additional passages of M12
and P69 cell line RNA; secondly, to ascertain whether our initial classification of the
selected miRs as tumour suppressors or oncomiRs was genuine through analysis of
additional model cell lines. This two-fold approach would allow for elimination of those
miRs that did not follow through as initially expected. Narrowing of the candidates could
be important, as the quantity of RNA extracted through laser-capture microdissection of
patient samples was expected to be low, and the number of miRs that could be
analyzed was finite. As was suspected, confirmatory single-miR RT-qPCR analysis of
the selected miRs showed correlative results in fold expression differences from P69 to
M12 for most, but not all, microRNAs selected (Table 3-4 and Appendix 1:Table 1).
While the results were mostly correlative in that oncomiRs typically were overexpressed
and tumour suppressors lost as compared to P69 levels, the level of those differences
was often highly variable. miRs 622, 221, and 299-3p were found to be so different that
they were opposite in expression as originally observed. These findings in particular
were repeated and confirmed with at least one additional RNA extraction. The
differences may have been due to the normalization parameters, as the panel data was
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Table 3-4: Expression differences are typically observed between Panel and
single miR “confirmatory” RT-qPCR analysis. RNA was isolated from different
passages of M12 and P69 cells than those used for the panel analysis, and subjected to
individual probing for selected miRs using LNA RT-qPCR. In both panel and single-miR
analysis, data was normalized (against the global mean in the panel, and against
RNU48 for single-miR analysis), and the expression level in M12 calculated relative to
the P69 cell line. Each sample was analyzed a minimum of three times. 299-5p results
appeared correlative, but the RNU48 amplification was atypical. miR-144 was
undetected for both P69 and M12 in single-miR analysis.
Expression differences between panel and single-miR analysis
133a
133b
9
622
199a-3p 147b
147
Panel
37.9
38.9
6.7
147.7
6.43
201.4
27.9
Single-miR
6.7
2.5
43.3
0.374
1.514
16.9
0.138

Panel
Single-miR

146a
0.459
0.021

488
0.526
0.039

221
0.783
1.39

127-3p
0.002
0.003
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127-5p
0.344
0.164

299-3p
11.4
0.035

299-5p
0.02
---

144
0.374
---

normalized to the global mean, while single-miR analyses were normalized to RNU48.
This could be expected to result in minor differences, but major discrepancies such as
those seen in miRs 622, 221, and 299-3p cannot be attributed to the normalization
method.
Each of the selected miRs was then further analyzed using the remainder of the
P69 progression model, as well as additional prostate cancer cell lines, in an effort to
determine which microRNAs warrant further investigation through modulation and target
confirmation. Through analyzing multiple prostate cancer and associated cell lines, we
hoped to gain confidence in our chosen miRs prior to using precious patient lasercapture microdissected RNA. Through this analysis, we chose those miRs that were
the most consistently expressed among the cell lines (depending on the nature of the
cell line), and/or those miRs that continued to intrigue us based on their targets or
known roles in carcinogenicity (Figures 3-2, 3-3, and 3-4, Appendix 1-Table 2).
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Figure 3-2: Relative Expression of oncomiR microRNAs in P69-M12 progression
model. miR levels were normalized to RNU48, and expression level calculated relative
to the P69 cell line. Each sample was analyzed in triplicate at minimum.
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Figure 3-3: Relative Expression of Tumour suppressor microRNAs in P69-M12
progression model. miR levels were normalized to RNU48, and expression level
calculated relative to the P69 cell line. Each sample was analyzed in triplicate at
minimum. M12 data for miR-299-5p was not included due to a discrepancy in RNU48.
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Figure 3-4: Relative Expression of microRNAs in additional prostate cell lines.
miR-levels were normalized to RNU48, and are expressed as the dCT (CT(miR) –
CT(RNU48)). A lower CT indicates higher expression. Each sample was analyzed in
triplicate at minimum.
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miR analysis of Laser-Capture Microdissected (LCM) prostate samples
Laser-captured microdissected samples were captured from 5 patient biopsies at
varying stage of prostate cancer. The majority of the tumours analyzed were classified
as Gleason 3, 4, or 5, and in some cases, it was only possible to isolate not only benign
and tumour tissue, but also stroma, lymphocyte, and/or venous tissue. miR LNA RTqPCR analysis of the 5 sets of patient samples revealed that, as expected, there is
considerable variability in the nature of the individual patient sample. A majority of the
miRs tested varied wildly from tumour to tumour; however, a few miRs assayed showed
consistency with their predicted role compared to the model cell lines (Figure 3-5,
Appendix 1: Table 3). In particular, miR-9 and miR-147b were strongly and consistently
oncomiRs in tumour samples, and miRs 299-3p and 199a-3p were consistently lower in
tumour samples than benign, and thus classified as potential tumour suppressors.
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OcomiR expression in prostate tumours
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Figure 3-5: Relative expression of microRNAs in laser capture microdissected
tissue samples. miR levels were normalized to RNU48, and expression level
calculated relative to the benign tissue of the same patient. Each sample was analyzed
in triplicate.
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DISCUSSION
Array analysis
Array analyses of cell lines, while they should not be used as the sole method for
identifying miRs that are modulated in neoplasias, can be an excellent launching point
for narrowing the potential candidates, provided that the cell line model is accurate to invivo processes. In prostate cancer work, some cell lines serve different purposes. For
example, the LNCaP series is an excellent model for identifying miRs that could
contribute to the pathways required for androgen independence. However, since the
LNCaP cell lines require coinjection with MS fibroblast cells for tumorigenesis and
metastasis in the later lines, they are not a good model for initial tumour development.
The P69/M12 progression model is the best model for human prostate cancer
tumorigenesis, and thus we felt that a miR array comparing those cell lines would best
catalogue modulated miRs in a manner most faithful to human tumorigenesis. Of the 15
miRs selected for further analysis, 10 of the 15 (67%) maintained their oncomiR or
tumour suppressor status in single miR analysis (Table 3-4). Unfortunately, that
indicates a relatively high (23%) incorrect read rate for miR analysis using panels.
There are a variety of technical reasons as to why panel analysis is more subject to
errors or inaccuracies, but one likely reason is that of stochastic effects. Splitting one
reverse transcription reaction across 768 wells is a dilution factor far above that used for
single-miR analysis, and the sheer chance of an accurate representation of all miRs in
the sample getting into each of those wells can be a factor in expression level variation.
Because of that concern, we ran technical duplicates of both M12 and P69 for Panel 1.
We found that there was high variability between the duplicate runs of Panel 1, and thus
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the miRs chosen from Panel 1 were those that were consistently modulated (up or
down) in both plates.
Variation between technical duplicates is well-known in miR microarray analysis;
a study evaluating and comparing locked-nucleic acid (LNA) arrays to bead-based and
Taqman low-density arrays found that the LNA inter-plate reproducibility was higher
than the other methods, at approximately 75%111, consistent with the findings presented
here. An additional study comparing microarray data to single-miR analysis found
anywhere from 0 to 10-fold differences in expression between the two platforms112,
similar to differences observed in this study.
miR 9
As a well-established miR involved in multiple cancers, miR-9 was not a
surprising find. miR-9 was overexpressed in all CaP cell lines analyzed, and in 3 of the
5 patient samples. Overexpression was dramatic, in the thousand-fold range for the
DU145 and PC3 cell lines, and a more reasonable overexpression level in M12 and
patient samples (2.5-78 fold higher than benign). There are only two reports on miR-9
in prostate cancer, one being a microarray study and the other focused on the
Androgen Receptor (AR). The microarray study found that miR-9 was the most
dramatic and consistently upregulated miR in prostate cancer, and was expressed as
an oncomiR in both low and high-grade regions within the same tumour113.
miR-9 has many well-established protein targets, in particular, e-cadherin, NFĸB, SOCS5 and ETS-1. A modest but consistent decrease in the androgen receptor
level has been shown when miR-9 was overexpressed in-vitro113, which could allow for
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an eventual switch from the early androgen-dependent tumour to a hormone-refractory
state.
miR-144
miR-144 has been well-characterized as a modulated microRNA in multiple
cancers. However, it seems to have different roles depending on tissue type, and as
such can be either an oncomiR (lung, esophageal, nasopharyngeal) or tumour
suppressor (bladder, bone, colorectal), depending on the cancer type. While our initial
panel analysis showed miR-144 as a tumour suppressor (0.37-fold downregulated in
M12 vs. P69), it was undetected in both P69 and M12 single-miR analyses, but highly
expressed in the M2182 and F6 lines. To further complicate the picture, patient LCM
samples showed significant upregulation in tumour compared to benign tissue from the
same patient, correlative with a recent microarray study reporting miR-144 as a
potential oncomiR for prostate cancer113. While the LNA technology used for miR
analysis in this study is highly specific for the miR in question, recent work in our
laboratory has found other miR RT-qPCR platforms to be more sensitive in detection,
and perhaps clarification of the P69 vs. M12 cell line analysis could be further
investigated using a different platform. This particular example highlights the need for a
thorough and balanced approach to miR discovery, using not only cell lines, but also
patient samples. Given the consistency in patient samples, miR-144 could be an
oncomiR in prostate cancer and warrants further investigation, although it would not be
recommended to use the P69/M12 progression line for miR-144 work.
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miR-221
miR-221 was highly inconsistent in CaP samples, both in cell line analysis and
patient samples. Initial panel analysis showed miR-221 to be slightly tumour
suppressive, with an average expression difference of 0.783 in M12 vs. P69 cells.
Single-miR analysis showed a 1.38-fold upregulation in the M12 line. Given known
error levels in miR panel analysis, this expression difference could be considered to be
within the range of error. Analysis of miR-221 in other cell lines and patient samples
was likewise inconsistent, the only exception being patient 09-362, who had
overexpression of miR-221 in not only tumour, but also stroma and lymphatic tissue
(Appendix 1, Table 3). Thus, miR-221 cannot be considered as an indicator miR for
prostate carcinoma, but may in fact still be a player in advanced prostate cancer: while
several studies report that miR-221 is lost in prostate cancer, others have shown that in
highly metastatic cancers, miR-221 is overexpressed in association with high-risk
carcinomas114 and plays a role in androgen independence17.
miR-488
The loss of miR-488 expression was even more impressive in single-miR
analysis as compared to the panel analysis (0.039 vs. 0.526-fold drop in expression in
M12 vs. P69). Similar expression levels to the metastatic M12 cell line were noted in
the PC3, DU145, and other prostate cell lines, which led us to believe that miR-488
could be a substantial tumour suppressor. Unfortunately, it was undetected in both
benign and tumour samples of all patients (Appendix 1, Table 3). Exiqon LNA RTqPCR is highly specific, but not as sensitive as other applications. Thus, evaluation with
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a different platform for miR RT-qPCR analysis could yield results. Additionally, a study
in 2011 was unable to detect miR-488 in the prostate cell lines (DU145, PC3, LNCaP),
but evaluated the miR regardless and found that it is able to affect androgen receptor
translation directly. They also found that when they added back miR-488, proliferation
and viability decreased, and apoptosis was enhanced115. Unfortunately, the literature
shows no correlation of miR-488 with any cancer, and expression is mainly seen in
neural development. miR-488 levels have also been shown to be so consistent in lung
cancer patient samples when comparing benign to tumour that it was proposed as a
potential normalization control116.
miRs-299-3p & 5p
miRs 299-3p and 5p were cast via panel analysis as opposite in expression, with
miR-299-3p an oncomiR and 299-5p as a tumour suppressor. This possibility was
rather intriguing, as it indicated that a shift in strand selection at the miR maturation
level. Unfortunately, the high relative level of expression for miR-299-3p did not
correlate under single-miR analysis, and multiple replicates of miR-299-3p analyzed in
P69 and M12 showed miR-299-3p expression lost in M12 as compared to P69.
Similarly, miR-299-3p was lost in PC3 cells as well. Of the five patients tested for miR299-3p, two had detectable levels in benign, with lost or lower expression of miR-299-3p
in tumour samples. The remaining 3 samples were undetected in tumour and benign
tissues. Thus, miR-299-3p appears to be consistently acting as a tumour suppressor, in
contrast to its originally perceived role as an oncomiR from the panel analysis. There is
no literature or proven targets for miR-299-3p, but many potential binding target
mRNAs, as predicted by miR prediction platforms86,87,89,117.
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miR-299-5p was identified as a tumour suppressor in the panel analysis, which
was confirmed by the single-miR analysis. Expression was similar between M2 and
PC3 cells, but the miR was undetected in DU145 cells. Patient analysis found that of
the 5 patients tested for miR-299-5p, two showed overexpression, in direct contrast to
that observed by the cell line analyses. Three patients had undetected levels of miR299-5p in both tumour and benign samples. Of the limited literature available for miR299-5p, it has been shown to act as a tumour suppressor in breast cancer, as loss of
miR-299-5p allows relief of suppression for the Osteopontin protein118, which is known
to play an important role in inflammation, tissue remodeling, invasion, migration, and
angiogenesis119. Osteopontin is also well-characterized as surging in expression during
the preosteoblast stage of bone cell development, which could parallel the CaP cell
integration in to bone metastases; moreover, increased osteopontin levels have been
observed in the LNCaP C4/C5/C4-2 androgen-independent sublines32. Given its
bimodal observed role in cell lines and patient samples, it is possible that analysis of
miR-299-5p with the LNCaP series could illuminate a potential hormone-dependent
switch.
miR-147
There is not a lot of literature regarding the expression of mIR-147 (also known
as miR-147a) in cancer, but it has been shown to act as both a tumour suppressor and
as an oncomiR in different cancers. Only one mRNA target has been proven, VEGFA,
which has been shown to stimulate angiogenesis, wound healing and tumour
development120. In our analyses, while the panel identified miR-147 as a potential
oncomiR (27.9-fold increased expression), single-miR analysis showed the opposite
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pattern, with M12 cells expressing 0.138 fold the level of the P69 cells. Because of this
inconsistency, we did not analyze the additional cell lines, and only tested one set of
patient LCM samples, in which miR-147 levels were undetected in both benign and
patient. Consequently, we do not consider miR-147 to have a consistent role in prostate
cancer.
miR-147b
miR-147b is one of the most consistent and promising potential oncomiRs to
develop from this study. Panel and single-miR confirmation showed this miR to be
highly upregulated (201 and 16-fold, respectively), and this high expression was
duplicated in other prostate cell lines, in a pattern consistent with the neoplastic and
metastatic nature of the cell lines tested (Figure 3-3). In particular, the levels of miR147b in PC3 cells were exceptionally high. Through patient LCM sample analysis, 4 of
the 5 patients showed significant upregulation, with an average of 11.1-fold
overexpression as compared to paired benign tissue (Appendix 1, Table 3). This miR is
relatively uncharacterized; it has not been described in any cancers, and has no known,
proven targets, although one study did some preliminary work using luciferase 3’-UTR
constructs and showed some modulation for a few target mRNAs44. However, the focus
was less on proving target binding and consequent effects and more on comparing
seed functionality to other miRs; thus, those targets have not been conclusively shown
as miR-147b targets. As a relatively unresearched microRNA, miR-147b will require
considerable research effort to hammer out its oncogenic mechanism.
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miR-622
While there is not a lot of literature regarding miR-622 in neoplasias, the literature
does agree that miR-622 is upregulated in some rectal cancers, particularly those
responsive to specific chemotherapeutics121 and those associated with Lynch
Syndrome122. However, one report showed that miR-622 acts as a tumour suppressor
in gastric cancer, with ING1 as a proven target, a component of the p53 pathway
involved in cell cycle arrest and apoptosis123. While expression of miR-622 in the panel
RT-qPCR was not replicated in single-miR analysis, PC3 and DU145 expressions were
relatively high, but so was the benign stromal line WMPY-1. Additionally, only 2 of the 5
patients sampled showed upregulation of miR-622; thus, unless additional patients are
sampled, it can’t be concluded with confidence that miR-622 is an oncomiR in CaP.
miRs-127-3p and 5p
miRs 127-3p and 5p expression levels were lower in M12 cells as compared to
P69, which was confirmed in single-miR analysis. They were not tested against the
additional prostate lines, but were tested against the patient LCM samples. three out of
five patients showed loss of expression in miR-127-3p in tumour compared to adjacent
benign tissue, as did three out of five for 127-5p (though not the same three patients for
both miRs). miR-127 deregulation has been shown in gastric and hepatocellular
cancer, specifically through epigenetic methylation silencing124,125. This silencing would
in fact silence both strands, thus making it more difficult to clarify which is having a more
pronounced effect on tumorigenesis or metastatic behavior.
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miR-127-3p has at least one proven target, MAPK4, which has already been
shown to be pivotal in gastric cancer invasion and metastasis124. miR-127-5p was
shown to attenuate MMP13 through 3’-UTR and western analysis, which moderately
promotes invasion and migration125. miR-127-5p and -3p certainly warrant further
investigation as a potential tumour suppressor set of microRNAs.
miRs-133a and b
miR-133a upregulation was consistent in single-miR analysis, but this
upregulation did not correlate with the other prostate cell lines tested, and only 2 of the
5 patient samples showed overexpression of miR-133a. While miR-133b yielded a
predictable cell line pattern, in that it was overexpressed in the benign hypertrophic cell
line BPH-04, as well as in the M12 cells (Appendix 1, Table 1), there was not an
appreciable overexpression in either DU145 or PC3 cells. Thus, this miR was not
analyzed with the limited cDNA created from the patient LCM samples. Both miRs have
been well-studied in other cancers as tumour suppressor miRs, and have several
proven and defined targets in the tumour suppression pathway, and thus they are
worthy of further research to clarify what is occurring in prostate samples.
miR-146a
Several studies have shown miR-146a as an oncomiR in prostate cancer, but
one report has shown that overexpression of miR-146a is associated with early stage,
androgen-dependent neoplasias, while a loss of function of miR-146a is essential for
androgen independent invasion and metastasis126. Single-miR analysis confirmed the
panel-identified loss of expression in M12 as compared to the benign P69, and so initial
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findings identified miR-146a as a tumour suppressor in cell line analysis. Unexpectedly,
only one patient’s tumour had detectable levels of miR-146a. The miR was
undetectable in the remaining 4 patient benign and tumour tissues.
miR-199a-3p
While miR-199a-3p was initially identified and confirmed as an oncomiR in the
P69/M12 progression model, in the 2 patients tested, it consistently showed a ~0.5 fold
loss of expression in tumour as compared to benign. The only tissue that it was
dramatically overexpressed was the stroma of one patient. miR-199a-3p has been
shown to act as both oncomiR and tumour suppressor in various cancers, and has
multiple proven targets to promote both natures; additional work may need to be
conducted to further evaluate miR-199a-3p’s role towards the progression of CaP, if
any.
Overall Conclusions & Future Directions
Analysis of a panel of over 700 miRs certainly generates a great deal of
information, such that one research laboratory couldn’t begin to track down each of the
modulated microRNAs. Based on bioinformatics analysis and literature research, 15
microRNAs were chosen that showed promise through the panel comparison of the
highly tumorigenic, metastatic M12s to the non-tumourigenic parental P69 line. This
comparison is the first of its kind in prostate cancer cell line research; only the P69/M12
progression can compare a poorly tumorigenic parental line to its metastatic,
tumorigenic subline that requires no coinjections to generate tumours in mice. Based
on the results of these analyses, a balanced approach including not only cell-line but
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also patient sample analysis allowed elimination of several candidates that appeared to
be dysresgulated. Of the 15 candidate miRs chosen for further analysis, 5 did not
correlate with single-miR analysis. Of the 14 miRs analyzed using patient LCM tissues,
only 5 (miR-9, miR-147b, miR-299-3p, miR-127-3p and miR-127-5p) showed sufficient
consistency between cell-line analyses and between patients to warrant further
investigation. Thus, a 33% success rate was achieved based on initially identified
dyseregulated microRNAs. The majority of the miRs selected for further investigation
are, for the most part, not well-described in prostate cancer, and the challenge will be to
identify those mRNA targets that lead to tumour progression through either a tumour
suppressor or oncomiR role.

87

Chapter 4
miR-147b is an oncomiR in prostate cancer and suppresses AATF
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INTRODUCTION
Previous work identified miR-147b as being up-regulated in not only prostate
cancer cell lines (Figure 4-1), but also in prostate cancer biopsy tumour samples as
compared to the benign laser-capture microdissected samples (Figure 4-2).
miR-147b is not well-studied, having been neither identified as an oncomiR or
tumour suppressor miR, nor has significant work been reported in proving potential
mRNA targets. miR-147b has a similar mature sequence to that of miR-147a38-41,
differing by only one base in the seed region (miR-147b – UGUGCG, miR-147a -UGUGUG). While miR-147a has a proven target in vascular endothelial growth factor A
(VEGFA), a protein known to be pro-angiogenic and pro-migration, there are no proven
targets for miR-147b.
Previously, mIR-147b has been labeled as miR-147 in some reports127, and is
found on chromosome 15q21.1128, specifically in the 3’-UTR of the normal mucosa of
esophagus-specific gene 1 protein (NMES1) (Figure 4-3). Interestingly, NMES1 siRNA
does not inhibit mature miR-147 levels in mice127. While there are several targets that
are predicted by various prediction software platforms (Table 4-1), none have been
proven thus far, and very few show potential as downregulated tumour suppressors.
miR-147b has an identical seed region to that of miR-210 (UGUGCG), and while
the two miRs have been shown to have some similarity in target effectiveness, they are
not completely duplicative in their target selection (Figure 4-4)44. While miR-210, 147a
and 147b have been shown to have some overlapping predicted targets, each also has
targets unique to the individual miR. Interestingly, the number of predicted targets for
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miR-147a is much higher than the sum of the miR-147b and miR-210 targets. It is
assumed that the remainder of the miR sequence has a role in target mRNA selection
as well, and thus this finding is not surprising. In our panel analysis of microRNA
expression in the P69-M12 cell lines, we found miR-210 to be overexpressed
approximately 2-fold in M12 cells as compared to P69. Given that miR-147b showed an
almost 17-fold overexpression, it is doing the bulk of the target repression in the M12
model if in fact miR-147b and miR-210 have similar regulatory objectives.
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relative miR-147b expression
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Figure 4-1 (Adapted from Chapter 3): miR-147b levels are upregulated in all
prostate cancer cell line models. A: miR-147b levels were measured in P69, M2182,
M12, and F6 cells. Data was normalized to RNU48 and expressed relative to P69 using
the comparative CT method. P69 and M12 cells were analyzed using 3 separate
extractions (p<0.05). B: miR-147b levels were measured in M12, DU145, and PC3
cells. Data was normalized to RNU48 (dCT) and expressed as a box plot. The dCT for
the P69 cell line is visualized as the red box.
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mimR-147b expression relative to benign tissue
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Figure 4-2 (Adapted from Chapter 3): miR-147b expression is upregulated in 80%
of tested patient tumours. miR-147b levels were measured in tumour and benign
tissue separated from prostate biopsies using laser-captured microdissection (LCM).
Data was normalized to RNU48 and expressed relative to the benign tissue using the
comparative CT method.
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miR-147b

NMES1 immature
transcript

15q21.1
NMES1 mature
transcript

Figure 4-3: The pre-miR-147b is located in the 3’-UTR of the NMES1 primary
transcript on chr15q21.1. NF-ĸB and STAT1α bind upstream of the pre-miRNA, and
activate expression. Mature miR-147b has been shown to develop from cloned primary
transcripts of NMES1, as well as being independently transcribed127. Blue represents
the untranslated regions (UTRs) of the NMES1 mRNA, shades of green represent the
exons, and yellow indicates the relative position of the miR-147b transcript.
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microRNA
hsa-miR-147a
hsa-miR-147b
hsa-miR-210

Sequence
guguguggaaaugcuucugc
gugugcggaaaugcuucugcua
cugugcgugugacagcggcuga

Figure 4-4: Similarities between miRs-147a, -147b, and -210. A: Table of miR
sequences. The seed region is highlighted in green. B: Targetscan analysis of
potential targets for miRs 147a, 147b, and 210. While 62 potential targets are in
common for all three miRs, each also has unique as well as overlapping mRNA targets.
(from Bertero et al.44)
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It is difficult to tease out early (2012 and previous) literature on the miR-147
family. Previous incarnations of the commonly used microRNA RT-qPCR arrays
(Applied Biosytems, Qiagen) had only “miR-147”, with no indication of sequence or A/B
specificity. In one instance, miR-147 was designated as such, but the Methods &
Materials section confirmed it to be miR-147b. In this report, Toll-like Receptor 2
(TLR2) and Type 1 Interferon (IFN) stimulation in mice induced miR-147b expression
through activation and subsequent binding of NF-ĸB and STAT1α to the miR-147
promoter. Inflammatory cytokine expression was subsequently attenuated through a
negative feedback loop127. This same study reported 3 potential NF-ĸB binding sites in
the mouse miR-147 promoter, two of which were shown through luciferase activity
assays to be responsive to NF-ĸB binding.
Given the remarkable consistency in upregulation of miR-147b in our work, not
only in prostate cancer cell lines, but also in patient samples, it was important to
evaluate how inhibition of miR-147b could impact the tumorigenicity of a prostate cancer
cell line model, and to identify potential tumour suppressor mRNA targets for miR-147b.
Project Aims
1. Inhibit miR-147b levels in the M12 cell line and evaluate any changes in
proliferation, tumorigenicity, or invasive potential.
2. Identify potential targets and pathways for a mechanism of miR-147b action.
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Methods and Materials
Cell Culture
Adherent cells were cultured in 75 cm2 flasks using RPMI 1640 supplemented
with L-Glutamine (Caisson Labs, North Logan, UT), 5% fetal bovine serum, 5 µg/mL
insulin, 5 µg/mL transferrin, 5 µg/mL selenium (ITS, Collaborative Research, Bedford,
MA). Gentamycin (0.05 mg/mL) was used to prevent bacterial contamination. Cells
were passaged when 50-65% confluent, and maintained for no longer than 20
passages. Passaging was accomplished by incubating with 0.25% Trypsin-EDTA
(Gibco-Life Technologies, Carlsbad, CA) for 5 minutes at 37°C, after which the trypsin
was inactivated by washing the cells in serum-containing media. The cells were then
pelleted through centrifugation at 1500xg for 5 minutes and either passaged, plated, or
pellets preserved. Cell pellets for analysis were produced by washing the pellet in 10
mL PBS, centrifugation at 1500xg for 5 minutes, removal of the supernatant, and flash
freezing in liquid nitrogen. Pellets were stored at -80°C for at least 24 hours.
Transfection
Stable transformations of an early passage of the M12 cell line with a vector
containing a miR-147b inhibiting sequence or scrambled control (pEZX-AM03,
Geneocopeia Inc., Rockville, MD) were performed using TransIT®-LT1 Transfection
Reagent (Mirus BIO LLC, Madison, WI, USA). Briefly, 1.5 x 105 cells were plated in a
25 cm2 flask in appropriate serum-containing media for 24 hours. The cells were then
rinsed with PBS, and serum-containing media replaced. The plasmid (6.5 µg) was
mixed with 650 µL of RPMI media with no serum or additives and 19.5 µL of TransIT®96

LT1 reagent at room temperature for 15-30 minutes. The solution was added dropwise
to each flask, and gently rocked back and forth. The transfections were incubated for
48 hours under standard cell culture conditions, and then selected for stable
transformants using 200 ng/mL of Puromycin or 300 ng/mL of Hygromycin for two
weeks. After the selection die-off, the cells were maintained using Puromycin (100
ng/mL) or Hygromycin (150 ng/mL).
RNA Isolation
RNA was isolated from cell pellets using the miRVanaTM RNA isolation method
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA),
eluted in 50 µL of Elution Buffer, and stored at -80°C. RNA concentration was
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad
Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (ThermoFisher Scientific, Inc., Waltham, MA).
Messenger RNA Analysis
Messenger RNA was quantified using reverse transcription-quantitative PCR
(RT-qPCR). Reverse transcription was accomplished using the iScript TM cDNA
Synthesis kit (Bio-Rad Laboratories). Briefly, 50 ng of RNA was mixed with 4 µL of the
5X iScript reaction mix, 1 µL of the iScript Reverse Transcriptase, and the volume
brought to 20 µL with nuclease-free water. The reaction mix was incubated for 5
minutes at 25°C, followed by 30 minutes at 42°C, and heat inactivation for 5 minutes at
85°C. Reactions were stored at -20°C until analysis. The qPCR reactions were
prepared by adding 3 µL of the prepared cDNA, 10 µM primer pairs for the relevant
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mRNA target (GAPDH: Forward: 5’-ACCACAGTCCATGCCATCAC; Reverse: 5’TCCACCACCCTGTTGCTGTA. AATF: Forward: 5’GACACGGACAAAAGGTATTGCG; Reverse: 5’-CCGGTGTTTTTGCAGAGTGG), 1X
FastStart Universal SYBR Green Master Mix (Roche Diagnostics, Indianapolis, IN), and
brought to 20 µL volume with nuclease-free water. qPCR was conducted in an Applied
Biosystems 7300 real-time PCR instrument (Life Technologies) using the following
conditions: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 95°C for
15 seconds, 55°C for 35 seconds, and 68°C for 35 seconds. Data was analyzed using
SDS software v1.3.1 (Life Technologies), using automatic threshold and baseline
settings. Each mRNA evaluated was analyzed in triplicate using a minimum of three
separate cell passage RNA extractions. GAPDH was used as a normalization control,
and relative expression was calculated using the comparative CT method85.
Western Blotting
Cultured cell pellets were lysed in 4% sodium dodecyl sulfate (SDS) in
phosphate-buffered saline (PBS) with 1X PhosSTOP phosphatase inhibitor (Roche
Diagnostics) and COMplete protease inhibitor (Roche Diagnostics), followed by
sonication for five minutes at 4°C. Protein concentration was calculated using the Dc
Protein Assay (Bio-Rad Laboratories), and absorbance read at 750 nm on the Smart
SpecTM 3000 Spectrophotometer (Bio-Rad Laboratories).
For western blotting, equal quantities of cell lysate (30-40 µg) were loaded onto a
Novex® 4-12% Tris-Glycine SDS polyacrylamide gel (Life Technologies), under
denaturing conditions using a loading buffer with 2% SDS, 5% β-Mercaptoethanol, 20%
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glycerol and 0.004% bromophenol blue in 0.125M Tris-HCl, and electrophoresed in a 25
mM Tris, 190 nM glycine, 0.1% SDS running buffer for approximately 90 minutes at 140
volts. The samples were transferred onto a Trans-Blot® nitrocellulose membrane (BioRad Laboratories) for 90 minutes at 200 mA and 4°C in a 48 mM Tris, 39 mM glycine,
0.04% SDS transfer buffer. Nonspecific binding was prevented by washing the blot for
30 minutes at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.05%
Tween-20 (TBST).

The blot was rinsed briefly in TBST, and incubated overnight (14-

20 hours) at 4°C in primary IgG antibody in 5% BSA in TBST. Primary antibodies used
were 1:1000 α-β-actin (C4) produced in mouse (Santa Cruz Biotechnologies, Inc.,
Santa Cruz, CA), 1:100 α-NF-kB produced in rabbit (Santa Cruz Biotechnologies, Inc)
and 1:500 α-AATF produced in mouse (Abnova, Tapiei, Taiwan),. After incubation in
primary antibody, the blot was washed with TBST four times for 5 minutes, followed by
incubation in secondary antibody (1:1000 α-mouse IgG-HRP produced in goat (Santa
Cruz Biotechnologies)) for 1 hour at room temperature. The blot was again washed
with TBST four times for 5 minutes, and luminol reaction developed using the Western
Lightning® chemiluminescent reagents (Perkin Elmer, Boston, MA). Western blots were
exposed and bands quantified using the ODYSSEY® Fc Imaging System (LI-COR
Biosciences, Lincoln, NE).
Proliferation Assay
M12 and M12 cells transformed with the miR-147b inhibitor plasmid (5,000 cells)
were plated into each well of a 24-well plate in triplicate. The adherent cells were
released by incubating with 0.25% Trypsin-EDTA (Gibco-Life Technologies) for 5
minutes at 37°C, after which the trypsin was inactivated by washing the cells in serum99

containing media. The cells were then pelleted through centrifugation at 1500xg for 5
minutes and the pellets resuspended in 1 mL of PBS, and counted using a Coulter
Counter® Analyzer (Beckman Coulter, Inc., Brea, CA) or Vi-Cell™ XR Cell Viability
Analyzer (Beckman Coulter, Inc) using a trypan blue solution. Cells were >90% live
when analyzed in this fashion.
Migration and Invasion Assays
For evaluation of migratory capabilities, M12 cells stably transformed with either
a scrambled control or miR-147b inhibitor were diluted in serum-free RPMI 1640
medium and 5 x 104 cells added to a ThinCert™ TC membrane support insert (Greiner
Bio-one BVBA/SPRL, Belgium) placed in the well of a 24-well plate. For invasion
assays, 30 µL of a 10% solution of Cultrex® Basement Membrane Extract (Growth
Factor Reduced), (R&D Systems®, Minneapolis, MN) in RPMI 1640 was pipetted onto
the membrane support insert, and incubated at 37°C for 1 hour prior to adding 1.25 x
106 cells to the upper chamber. For both assays, 1 mL of RPMI 1640 medium
containing 5% FBS and 10 ng/mL EGF was pipetted into the lower chamber of the well
as the chemoattractant. The unit was incubated for 24 hours. Media was aspirated and
cells were fixed by adding 0.025% of gluteraldehyde in ddH2O to the bottom chamber
for 20 minutes, followed by staining with 0.1% leucocrystal violet in 10% EtOH and PBS
for a minimum of 30 minutes. The membranes were excised and mounted to a
microscope slide using Permount® (Fisher Scientific, Waltham, MA). Cell counts
representing migratory or invasive cells were performed in 5 random fields for each
replicate, averaged, and expressed as relative to the control. Data was the result of a
minimum of 3 independent experiments, each performed in triplicate.
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In-Vivo studies
M12 and M12 cells stably transformed with the miR-147b inhibitor plasmid
(1x106) were subcutaneously (SC) injected into 10 (5 for each treatment) male athymic
nude mice (Harlan Laboratories, Inc., Indianapolis, IN) to assess tumorigenicity.
Tumour growth was monitored with caliper measurement and tumour volume calculated
as length x width2/2 (mm3) over a period of 45 days until sacrifice. All experiments were
conducted under a protocol approved by the Institution Animal Care and Use
Committee of Virginia Commonwealth University (VCU).
Data Analysis
Data were presented as the mean ± standard deviation. Statistical analyses
were conducted in the Microsoft® Excel software platform, using the independent
Student's t-test, assuming equal variance between the two groups. Statistical
significance was defined as p ≤ 0.05.
Results
Inhibition of miR-147b in the M12 cells had significant effects on migratory and
invasive potential of the highly metastatic cell line (p <0.001 for both assays) (Figure 45). Additionally, stable transfection with a miR-147b inhibitor inhibited proliferation in
M12 cells by an average of 58.5% (p <0.03) (Figure 4-6). This inhibition is uncommon
in our experience in this cell line progression model, as the cells have been
immortalized via SV40T, which is known to bind to the Rb protein and prevent the Rbmediated cell-cycle stop at G1129 (reviewed in Dick et al.130). Thus, we would predict
that a target of miR-147b would be a tumour suppressor protein involved in cell cycle
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progression. Inhibition of miR-147b results in loss of translation suppression of that
tumour suppressor, which can then act on the cell cycle as a stop signal, and
consequently, cell doubling times are reduced.
Cells (1x106) were injected subcutaneously into the flanks of nude athymic mice
and monitored for tumour volume for up to 47 days after injection. M12 cells with the
miR-147b inhibitor showed a significantly lower level of tumour growth (p=.085) (Figure
4-7). All mice (with the exception of one M12 injected mouse) developed tumours.
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Figure 4-5: Inhibition of miR-147b significantly reduces migratory and invasive
potential. M12 cells were stably transformed with scrambled control or miR-147b
inhibitor, plated on a ThinCert transwell membrane (with basement membrane added
for invasion assay) and assessed for (A) migratory (p < 0.001) and (B) invasive potential
(p < 0.001). Data is the mean of 3 independent experiments, each performed in
triplicate.
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Figure 4-6: Cell proliferation is impacted by miR-147b inhibition. Inhibition
resulted in a 58.5% reduction in proliferation (p < 0.03). Results are representative of 4
independent experiments, each performed in triplicate.
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Figure 4-7: Tumour growth is significantly reduced upon miR-147b
inhibition. Subcutaneous injections of the respective cell lines into the flank of nude
athymic mice. Tumour reduction was consistently observed (p = .085). Results are
reported as the average ratio of tumour volume to the final average M12 tumour
volume. N=5 mice for each treatment.
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Given our observations of the difference in oncogenic potential when miR-147b is
inhibited, we felt confident that this miR has at least one significant target that would
prevent tumour progression when released from suppression. We therefore focused
our efforts on identifying potential targets for activation.
NF-ĸB is one of the potential activators of miR-147b transcription and thus we
were interested in determining if it was upregulated, and the consequent cause of the
observed increase in miR-147b levels. However, western blot analysis did not indicate
a change in NF-ĸB levels (Figure 4-8). Thus, we do not view it as the source of the
miR-147b upregulation.
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Figure 4-8: NF-kB levels are not increased in M12 cells, and thus likely not
contributing to increased miR-147b expression. Western blot analysis of NF-kB and
β-Actin as loading control. Blot is representative of 2 independent experiments.
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As there are no absolutely proven targets for miR-147b, a search for potential
targets is literally a fishing expedition. While the majority of miR binding events occur in
the 3’-UTR of the messenger RNA, a growing body of literature has shown that miRs
can bind and modulate mRNA translation throughout the message, including the 5’-UTR
and coding regions98,99. This certainly complicates the search, as the majority of miRtarget prediction software platforms search the 3’-UTRs of genes alone. We first turned
to miR-prediction software platforms for identification of potential targets. Review of the
most commonly identified, highest confidence mRNA targets using TargetScan 92-94,110,
TargetMiner90, miRDB86,87,89,117, and Diana88 resulted in a large list. Upon identifying
targets, we reviewed the seed-pairing potential between miR and mRNA, and
performed a literature search to determine each protein’s known role, possible
correlations to malignancy. The majority of proteins identified as having high seedpairing capability to mIR-147b were either not previously shown to be modulated in
cancers, or were in fact being upregulated in tumours and thus would not likely be
active targets for translation suppression by miR-147b in the prostate. The only protein
identified that had a known tumour-suppressive role in cancers was AATF, or apoptosisantagonizing transcription factor.
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Table 4-1: Top predicted targets for miR-147b by bioinformatic analysis.
Evaluation of the top potential mRNA candidates from 3 different miRNA target mining
software programs, DIANA, miRDB, and TargetScanHuman, release 6.2, revealed that
with the exception of AATF, none of the top targets have known tumour suppressive
function.

Protein

Abbreviation

NADH
dehydrogenase
(ubiquinone) 1
alpha subcomplex,
4

NDUFA4

scavenger receptor
class A, member 3

SCARA3

insulin-like growth
factor 2
(somatomedin A)
apoptosis
antagonizing
transcription factor
polymerase (RNA)
III (DNA directed)
polypeptide F
zinc finger protein 3
homolog (mouse)
potassium voltagegated channel,
shaker-related
subfamily, member
3

IGF2

AATF

POLR3F
ZFP3

KCNA3

Function

NADH dehydrogenase activity and
oxidoreductase activity – transfers
NADH to ubiquinone;
mitochondrial respiratory chain,
complex I
macrophage scavenger receptorlike protein which deplete reactive
oxygen species; induced by
oxidative stress.
insulin family of growth factors,
the predominant growth factor in
adults.
interacts with c-Jun in the
apoptotic pathway
Subunit of RNA Polymerase III,
transcribes ribosomal and tRNA
genes
May be involved in transcriptional
regulation
Voltage-gated potassium channel,
essential in T-Cell proliferation and
activation

Homeobox C6

HOXC6

Transcription factor involved in
development

Zinc finger protein
148

ZNF148

Transcriptional effector involved in
cell growth and death

Brain-derived
neuotrophic factor

BDNF

Nerve growth factor involved in
striatal neurons

Homeobox A9

HOXA9

Trancription factor involved in
morphogenesis and differentiation
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Role in Carcinogenicity?

Predicted
by:

Unknown

DIANA,
miRDB
TargetScan

mRNA up in ovarian tumours compared
to breast131

DIANA

Tumour progression through initiation of
steroidogenesis132,133
DIANA
High levels in many cancers through loss
of epigenetic control, including prostate
Overexpression induces apoptosis
May stimulate Androgen Receptor (REF)

DIANA

Unknown

DIANA,
miRDB

unknown

miRDB

Upregulated in rat prostate cancer cell
lines

miRDB

Upregulated in gastric cancer
Deregulated in head and neck squamous
cell carcinoma
Upregulated in prostate cancer134
Upregulated in colorectal cancer
Effector of Vimentin
Decreased in colorectal cancer pt serum
Elevated in gastric cancer
High expression associated with poor
prognosis in lung cancer
Elevated in ovarian, prostate,
meningioma, oral cancer
Decreased in bladder cancer

TargetScan

TargetScan

TargetScan

TargetScan

The Apoptosis-Antagonizing Transcription Factor (AATF) was first isolated in
rats, and subsequently in humans during a search for TGF-β regulated genes involved
in the differentiation of intestinal crypt cells135. It is located on chromosome 17q11.2q12, and is also known as Che-1136,137. The protein contains 560 amino acids, a
nuclear localization signal, three nuclear hormone receptor LXXLL binding motifs, a
leucine zipper motif, and several phosphorylation sites for different kinases 135,137. AATF
is expressed in every tissue, but expression is enriched in brain, heart, thymus, kidney,
and placenta135. Interestingly, AATF shares homology with SV40 large T antigen as
well as with E. coli ς-factor 70, and interacts with the Rb protein in a similar fashion to
SV40T138. As an RNA Polymerase-II binding protein, AATF has been shown to have a
key role in cellular processes including DNA damage response, cell-cycle control,
chromatin remodeling, and apoptosis139.
Evaluation of AATF message and protein expression was consistent with it being
regulated by miR-147b (Figure 4-9). Western blot analysis indicated that while low in
abundance, AATF is certainly detectable in P69 and the M12 cells treated with miR147b inhibitor. However, the AATF signal was not visible in the M12 cell lysates.
Additionally, RT-qPCR analysis showed that AATF messenger RNA levels are also
being modulated by miR-147b. As in our evaluation of the c-KIT message (Chapter 3),
AATF mRNA must be cleaved by the miR-147b/Argonaute 2 complex in order for
messenger RNA levels to be changed between the cell lines. While there could be and
is a considerable level of complexity between the P69 and M12 cells (Chapter 2),
modulation between the M12 and M12 treated with mIR-147b inhibitor could only be
caused by miR-147b cleavage.
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Figure 4-9: messenger RNA and protein levels are returned to P69 levels by miR147b inhibition. AATF expression in the P69, M12, and M12 stably transformed with
vector expressing miR-147b inhibitor. A: Western blot analysis and B: quantitation.
Blot and quantitation are representative of 2 independent experiments, normalized to βActin and reported as relative to the M12 cell line. C: messenger RNA relative
quantitation shows that mRNA levels are impacted by miR-147b, and inhibition reverts
levels to P69 levels (p<0.03 for P69 and miR-147b inhibited lines vs. M12). mRNA is
normalized to GAPDH and reported as relative to the M12 cell line. Results are
compiled data from two biological replicates, each performed in triplicate.
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The AATF 3’-UTR is very short, approximately 207 nucleotides long. Analysis of
the AATF 3’-UTR using TargetScan and RNAHybrid revealed no sites in the 3’-UTR
where miR-147b might bind. Analysis of the entire messenger RNA using RNAHybrid
and Diana identified six excellent potential matches, all with free energy values below 22 kcal/mol (Table 4-2).
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Table 4-2: Top potential binding sites for miR-147b are within the coding regions
of the mRNA. Binding sites are ordered by descending free energy values. Adapted
from RNAHybrid86,87 analysis of AATF mRNA (NM_012138.3).
position 665 (Exon 1)
target 5' G
CAC
AAA A 3'
AGCAGAAGC
UCUGCA
AC
UCGUCUUCG
AGGCGU
UG
miRNA 3' A
UAA
G
5'
mfe: -30.7 kcal/mol
position 190 (5’-UTR)
target 5' G
C GG GU GGG
U 3'
GGC G G U
CCGCACAU
UCG C C A
GGCGUGUG
miRNA 3' A
U UU GU AA
5'
mfe: -29.2 kcal/mol
position 105 (5’-UTR)
target 5' G
UGU GG
GCC
G 3'
AGC
G GUG
UCCGCGCG
UCG
C CGU
AGGCGUGU
miRNA 3' A
U
UU
AA
G 5'
mfe: -27.8 kcal/mol
position 58 (5’-UTR)
target 5' C
CCCC CCCCUC
C 3'
GCAGG
GC
CCGCGCGC
CGUCU
CG
GGCGUGUG
miRNA 3' AU
U
UAAA
5'
mfe: -25.2 kcal/mol
position 1305 (Exon 5)
target 5' A
CUUUGCCGAC
ACAGUCUACAGGAA
U 3'
UGGCA AAGCG
UUU
CCGCACAC
AUCGU UUCGU
AAA
GGCGUGUG
miRNA 3'
C
5'
mfe: -24.3 kcal/mol
position 507 (Exon 2)
target 5'
U
GAC
G 3'
GGGAGCA
UCUGC CA
UCUUCGU
AGGCG GU
miRNA 3' AUCG
AA
U G 5'
mfe: -22.9 kcal/mol
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Discussion
In this report, we sought to confirm miR-147b’s previously identified status as an
oncomiR, which was based not only on analysis of the poorly-tumorigenic P69 and its
highly metastatic subline M12, but also other well-established prostate cancer cell lines,
and finally through confirmation using human biopsy samples retrieved by laser-capture
microdissection. Inhibition of miR-147b in M12 cells resulted in markedly reduced cell
proliferation, and reduced migratory and invasive potential. Tumour growth in-vivo was
also reduced in male nude athymic mice when miR-147b was inhibited.
We also hoped to identify potential proteins whose mRNAs were targets of miR147b, thus elucidating a mechanism for the observed oncogenic effects. Through a
combination of bioinformatics analyses and literature reviews of potential targets, we
identified AATF as a strong candidate for miR-147b targeting. AATF appears to act
either as an oncogene or tumour suppressor, and its action is strongly dependent on the
tumour origin. It is known to interact with subunit 11 of RNA Polymerase II, and repress
growth arrest by activation of p21, a cyclin-dependent kinase inhibitor138,140. The same
study showed that a significant amount of AATF is complexed with Rb protein, and
competes with Rb-recruited HDAC1 for binding, which can lead to dysregulation of
proliferation targets140.
AATF also has a known role as an oncogene. In breast cancer and leukemia,
AATF is known to be upregulated, likely through the c-Myc response element in its
promoter141. RNA interference with AATF message results in decreased cell
proliferation and induction of apoptosis through down-regulation of Bcl2 and up-
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regulation of Bax139. AATF is also known to interact with the tumour suppressor Rb,
releasing repression on E2F-mediated transcription137, and is implicated in co-activation
of the androgen receptor137,142. Some research has shown that AATF is phosphorylated
and stabilized upon DNA damage, and in a p53-dependent manner, AATF works to
modulate the G2/M checkpoint143.
The low levels observed in the prostate cell lines here described are consistent
with observed down-regulation in kidney and colon carcinomas140. In-vitro,
overexpression of AATF in human colon carcinoma cells caused cell accumulation at
the G1 checkpoint, and directly stimulated p21 transcription in a p53-independent
manner140. Such a block would be consistent with our observations of reduced cell
proliferation when miR-147b was inhibited (Figure 4-5), and AATF consequently
upregulated. This results in competitive binding over HDAC1 for the SP1 binding sites
of p21, and therefore transcription of the tumour suppressor (Figure 4-10). Interestingly,
NMES-1, the gene in which miR-147b is located, has been shown to be downregulated
in colon and esophageal carcinoma tumour tissues144,145. If miR-147b levels were found
to be upregulated in these tissues as well, it would indicate that miR-147b is being
selectively overexpressed, as compared to being overexpressed during the
overexpression of NMES1.
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A: Benign State

B: Tumour State

Figure 4-10: Proposed mechanism of miR-147b action on cell cycle progression.
A: In the benign state, miR-147b is not well-expressed, and thus AATF protein is
produced and can interact with the SP1 binding sites on the p21 protein, outcompeting
HDAC1. B: In the neoplastic cell, miR-147b is overexpressed in prostate, colon, and
kidney carcinomas, and acts to cleave and reduce AATF message, thus allowing for
deacetylation of the p21 gene and consequently less transcription, which leads to loss
of the tumour suppressor protein and an increase in cell cycle progression.
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Our results show a significant effect of miR-147b on AATF through mRNA and
western blot analysis of protein levels. Thus, there is certainly a tie between miR-147b
and AATF. In order to prove that this interaction is a direct effect by miR-147b and not
suppression through an indirect manner, cloning wild type and mutated versions of each
of the seven potential binding sites of the miR-147b mRNA into 3’-UTR luciferase
constructs will need to be undertaken. This final group of experiments will elucidate the
manner of action of miR-147b on the AATF protein levels.
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Chapter 5:
miR-9 acts as an oncomiR in prostate cancer by regulation of e-cadherin and
SOCS5 through multiple pathways that drive towards tumour progression and
metastasis
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Previous work identified miR-9 as up-regulated in not only prostate cancer cell
lines (Chapter 3), (Figure 5-1), but also in 3 out of 4 of prostate cancer biopsy tumour
samples as compared to the benign laser-capture microdissected tissue (Figure 5-2).
The consistency and high expression of miR-9 in the majority of samples analyzed led
to an investigation of miR-9’s mode of action in prostate cancer.
miR-9 has been well characterized in neural tissue development (reviewed in
Yuva-Aydemir et al.146), but is detectable in a variety of human tissues. miR-9 is a
family of three identical sequences (ucuuugguuaucuagcuguauga). These 3
homologues are designated as miR-9-1, 9-2, and 9-3. miR-9-1 is located within an
open reading frame on chr 1q22, miR-9-2 is located within the reading frame of a LNCRNA on chr 5q14.3, and miR-9-3 is located on chr15.26.1. The miR-9-3 locus has Myc
and MycN binding sites that have been shown to activate miR-9 expression43. In at
least one instance, miR-9 has been upregulated through action of Prospero Homeobox
1 (PROX1)29.
While hundreds of putative miR-9 targets have been identified through a variety
of miR-target prediction programs, only six have been definitely proven as being directly
targeted by miR-9; i.e., that miR-9 binds to a portion of the mRNA, and that binding
affects protein levels (Table 5-1).
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Figure 5-1 (Adapted from Chapter 3): miR-9 levels are upregulated in all prostate
cancer cell line models. A: miR-9 levels were measured in P69, M12, M2182, and F6
cells. Data was normalized to RNU48 and expressed relative to P69 using the
comparative CT method. B: miR-9 levels were measured in M12, DU145, WMPY1 and
PC3 cells. Data was normalized to RNU48 (dCT) and expressed as a box plot. The dCT
for the P69 cell line is visualized as the red box.
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Figure 5-2 (adapted from Chapter 3): miR-9 expression is upregulated in 60% of
tested patient tumours. miR-9 levels were measured in tumour and benign tissue
separated from prostate biopsies using laser-captured microdissection (LCM). Data
was normalized to RNU48 and expressed relative to the benign tissue using
comparative CT method. miR-9 was undetected in both benign and tumour
of Pt 09-225.
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Table 5-1: Proven direct targets of miR-9. The targets listed have been proven
through both luciferase assay analysis and mutation of the 3’-UTR, as well as at least
one additional analytical technique (western blot of protein level, microarray, etc.).
mRNA target

Shown in

e-cadherin
NF-kB

Breast cancer
Metastatic melanoma

CXCR4

Nasopharyngeal carcinoma

BRCA1

Ovarian Cancer
Human embryonic stem cells147

Stathmin
SOCS5

Non-small cell lung cancer and
melanoma cell lines
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E-cadherin has been described as a direct target for miR-9 in multiple instances,
including colon, hepatocellular, and breast cancer20,148,149. E-cadherin (CDH1) is a
transmembrane glycoprotein that forms adherens junctions between adjacent epithelial
cells. The cytoplasmic tail associates with intracellular proteins, ultimately linking the
adherens junctions to the actin cytoskeleton24,150,151. The extracellular domain of ecadherin interacts with e-cadherin from neighboring cells to form adherent sheets of
epithelial cells20,152.
NF-kB is also known to be a direct target of miR-9. While NF-kB is known to be
activated in an inflammatory response and early tumour apoptosis, ultimately many
neoplasias show constitutive activation of NF-kB and transcription of pro-survival gene
products153,154. NF-kB activity as related to miR-9 appears to occur in the cancers
where miR-9 expression is lost, and NF-kB is consequently upregulated155,156. Many of
the cancers describing miR-9 overexpression do not note a change in NF-kB levels, and
thus competitive binding for miR-9 or promoter elements in NF-kB may be the cause for
the lack of observed change in miR-9 overexpressing carcinomas.
Suppressor of Cytokine Signalling, or SOCS5, are a family of proteins that work
to inhibit downstream JAK/STAT signaling through inhibition of STAT phosphorylation
by multiple actions. Some SOCS proteins bind and inhibit JAK kinases, while others
compete with STATs for phosphotyrosine binding sites on cytokine receptors157. SOCS
proteins also interact with the ubiquitination machinery through a motif called the SOCS
box to ubiqitinate the signaling intermediates and thus reduce signal transduction 158.
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Given the consistent upregulation of miR-9 in prostate cancer cell lines and
patient samples as described in Chapter 3, it was important to evaluate how inhibition of
miR-9 could impact the tumorigenicity of a prostate cancer cell line model, and to
evaluate known targets of miR-9 as affecting tumour progression in prostate cancer.
Project Aims
3. Inhibit miR-9 levels in the M12 cell line and evaluate any changes in proliferation,
tumorigenicity, or invasive potential.
4. Evaluate potential target mRNAs in prostate cancer; confirm the mode of action of
miR-9 as inhibiting e-cadherin and SOCS5 protein expression, thus promoting the
EMT transition and angiogenesis through multiple pathways.

Methods and Materials
Cell Culture
Adherent cells were cultured in 75 cm2 flasks using RPMI 1640 supplemented
with L-Glutamine (Caisson Labs, North Logan, UT), 5% fetal bovine serum, 5 µg/mL
insulin, 5 µg/mL transferrin, 5 µg/mL selenium (ITS, Collaborative Research, Bedford,
MA). Gentamycin (0.05 mg/mL) was used to prevent bacterial contamination. Cells
were passaged when 50-65% confluent, and maintained for no longer than 20
passages. Passaging was accomplished by incubating with 0.25% Trypsin-EDTA
(Gibco-Life Technologies, Carlsbad, CA) for 5 minutes at 37°C, after which the trypsin
was inactivated by washing the cells in serum-containing media. The cells were then
pelleted through centrifugation at 1500xg for 5 minutes and either passaged, plated, or
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pellets preserved. Cell pellets for analysis were produced by washing the pellet in 10
mL PBS, centrifugation at 1500xg for 5 minutes, removal of the supernatant, and flash
freezing in liquid nitrogen. Pellets were stored at -80°C for at least 24 hours.
Transfection
Stable transformations of an early passage of the M12 cell line with a vector
containing a miR-9 inhibiting sequence or scrambled control (pEZX-AM03,
Geneocopeia Inc., Rockville, MD) were performed using TransIT ®-LT1 Transfection
Reagent (Mirus BIO LLC, Madison, WI, USA). Briefly, 1.5 x 105 cells were plated in a
25 cm2 flask in appropriate serum-containing media for 24 hours. The cells were then
rinsed with PBS, and serum-containing media replaced. The plasmid (6.5 µg) was
mixed with 650 µL of RPMI media with no serum or additives and 19.5 µL of TransIT ®LT1 reagent at room temperature for 15-30 minutes. The solution was added dropwise
to each flask, and gently rocked back and forth. The transfections were incubated for
48 hours under standard cell culture conditions, and then selected for stable
transformants using 200 ng/mL of Puromycin or 300 ng/mL of Hygromycin for two
weeks. After the selection die-off, the cells were maintained using Puromycin (100
ng/mL) or Hygromycin (150 ng/mL).
RNA Isolation
RNA was isolated from cell pellets using the miRVanaTM RNA isolation method
according to the manufacturer’s protocol (Ambion-Life Technologies, Carlsbad, CA),
eluted in 50 µL of Elution Buffer, and stored at -80°C. RNA concentration was
estimated using either the Smart SpecTM 3000 Spectrophotometer (Bio-Rad
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Laboratories, Hercules, CA) or the NanoDrop ND-2000 Spectrophotometer (ThermoFisher Scientific, Inc., Waltham, MA).
Messenger RNA Analysis
Messenger RNA was quantified using reverse transcription-quantitative PCR
(RT-qPCR). Reverse transcription was accomplished using the iScriptTM cDNA
Synthesis kit (Bio-Rad Laboratories). Briefly, 50 ng of RNA was mixed with 4 µL of the
5X iScript reaction mix, 1 µL of the iScript Reverse Transcriptase, and the volume
brought to 20 µL with nuclease-free water. The reaction mix was incubated for 5
minutes at 25°C, followed by 30 minutes at 42°C, and heat inactivation for 5 minutes at
85°C. Reactions were stored at -20°C until analysis. The qPCR reactions were
prepared by adding 3 µL of the prepared cDNA, 10 µM primer pairs for the relevant
mRNA target (GAPDH: Forward: 5’-ACCACAGTCCATGCCATCAC; Reverse: 5’TCCACCACCCTGTTGCTGTA. E-Cadherin: Forward: 5’GGTGCTCTTCCAGGAACCTC; Reverse: 5’-GAAACTCTCTCGGTCCAGCC. SOCS5:
Forward: 5’-CCTCCTTCGGCCTTCACCTA; Reverse: 5’TATAAAATCGTGACCAATAGCAGGC), 1X FastStart Universal SYBR Green Master
Mix (Roche Diagnostics, Indianapolis, IN), and brought to 20 µL volume with nucleasefree water. qPCR was conducted in an Applied Biosystems 7300 real-time PCR
instrument (Life Technologies) using the following conditions: 50°C for 2 minutes, 95°C
for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for 35 seconds, and
68°C for 35 seconds. Data was analyzed using SDS software v1.3.1 (Life
Technologies), using automatic threshold and baseline settings. Each mRNA evaluated
was analyzed in triplicate using a minimum of three separate cell passage RNA
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extractions. GAPDH was used as a normalization control, and relative expression was
calculated using the comparative CT method12.
Western Blotting
Cultured cell pellets were lysed in 4% sodium dodecyl sulfate (SDS) in
phosphate-buffered saline (PBS) with 1X PhosSTOP phosphatase inhibitor (Roche
Diagnostics) and COMplete protease inhibitor (Roche Diagnostics), followed by
sonication for five minutes at 4°C. Protein concentration was calculated using the Dc
Protein Assay (Bio-Rad Laboratories), and absorbance read at 750 nm on the Smart
SpecTM 3000 Spectrophotometer (Bio-Rad Laboratories).
For western blotting, equal quantities of cell lysate (30-40 µg) were loaded onto a
Novex® 4-12% Tris-Glycine SDS polyacrylamide gel (Life Technologies), under
denaturing conditions using a loading buffer with 2% SDS, 5% β-Mercaptoethanol, 20%
glycerol and 0.004% bromophenol blue in 0.125M Tris-HCl, and electrophoresed in a 25
mM Tris, 190 nM glycine, 0.1% SDS running buffer for approximately 90 minutes at 140
volts. The samples were transferred onto a Trans-Blot® nitrocellulose membrane (BioRad Laboratories) for 90 minutes at 200 mA and 4°C in a 48 mM Tris, 39 mM glycine,
0.04% SDS transfer buffer. Nonspecific binding was prevented by washing the blot for
30 minutes at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.05%
Tween-20 (TBST).

The blot was rinsed briefly in TBST, and incubated overnight (14-

20 hours) at 4°C in primary IgG antibody in 5% BSA in TBST. Primary antibodies used
were 1:1000 α-β-actin (C4) produced in mouse (Santa Cruz Biotechnologies, Inc.,
Santa Cruz, CA), 1:2500 α-e-cadherin (CDH1) produced in mouse (Sigma Aldrich, St.
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Louis, MO), 1:100 α-NF-kB produced in rabbit (Santa Cruz Biotechnologies, Inc), and
1:500 α-SOCS5 (M-300) produced in rabbit (Santa Cruz Biotechnologies),. After
incubation in primary antibody, the blot was washed with TBST four times for 5 minutes,
followed by incubation in secondary antibody (1:1000 α-mouse IgG-HRP produced in
goat (Santa Cruz Biotechnologies) and/or 1:1000 α-rabbit IgG-HRP produced in goat
(Cell Signalling Technology, Danvers, MA), for 1 hour at room temperature. The blot
was again washed with TBST four times for 5 minutes, and luminol reaction developed
using the Western Lightning® chemiluminescent reagents (Perkin Elmer, Boston, MA).
Western blots were exposed and bands quantified using the ODYSSEY® Fc Imaging
System (LI-COR Biosciences, Lincoln, NE).
Proliferation Assay
M12 and M12 cells transformed with the miR-9 inhibitor plasmid were plated
(5,000 cells) onto a 24-well plate in triplicate. The adherent cells were released by
incubating with 0.25% Trypsin-EDTA (Gibco-Life Technologies) for 5 minutes at 37°C,
after which the trypsin was inactivated by washing the cells in serum-containing media.
The cells were then pelleted through centrifugation at 1500xg for 5 minutes and the
pellets resuspended in 1 mL of PBS, and counted using a Coulter Counter ® Analyzer
(Beckman Coulter, Inc., Brea, CA) or Vi-Cell™ XR Cell Viability Analyzer (Beckman
Coulter, Inc) using a trypan blue solution. Cells were >90% live when analyzed in this
fashion.
Migration and Invasion Assays
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For evaluation of migratory capabilities, M12 cells stably transformed with either
a scrambled control or miR-9 inhibitor were diluted in serum-free RPMI 1640 medium
and 5 x 104 cells added to a ThinCert™ TC membrane support insert (Greiner Bio-one
BVBA/SPRL, Belgium) placed in the well of a 24-well plate. For invasion assays, 30 µL
of a 10% solution of Cultrex® Basement Membrane Extract (Growth Factor Reduced),
(R&D Systems®, Minneapolis, MN) in RPMI 1640 was pipetted onto the membrane
support insert, and incubated at 37°C for 1 hour prior to adding 1.25 x 10 6 cells to the
upper chamber. For both assays, 1 mL of RPMI 1640 medium containing 5% FBS and
10 ng/mL EGF was pipetted into the lower chamber of the well as the chemoattractant.
The unit was incubated for 24 hours. Media was aspirated and cells were fixed by
adding 0.025% of gluteraldehyde in ddH2O to the bottom chamber for 20 minutes,
followed by staining with 0.1% leucocrystal violet in 10% EtOH and PBS for a minimum
of 30 minutes. The membranes were excised and mounted to a microscope slide using
Permount® (Fisher Scientific, Waltham, MA). Cell counts representing migratory or
invasive cells were performed in 5 random fields for each replicate, averaged, and
expressed as relative to the control. Data was the result of a minimum of 3 independent
experiments, each performed in triplicate.
In-Vivo studies
M12 and M12 cells transformed with the miR-9 inhibitor plasmid (1x106 cells)
were subcutaneously (SC) injected into 10 (5 for each treatment) male nude athymic
mice (Harlan Laboratories, Inc., Indianapolis, IN) to assess tumorigenicity. Tumour
growth was monitored with caliper measurement and tumour volume calculated as
length x width2/2 (mm3) over a period of 45 days until sacrifice. To assess metastatic
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potential, three male athymic nude mice were orthotopically injected with (1x10 6 cells) of
M12 or M12 cells transformed with the miR-9 inhibitor plasmid. The mice were
sacrificed at 76 days, and peritoneal metastatic sites were counted. All experiments
were conducted under a protocol approved by the Institution Animal Care and Use
Committee of Virginia Commonwealth University (VCU).
3’-UTR constructs
A portion of the 3’-UTR of e-cadherin was previously cloned into pmiR-Report,
the seed region subsequently mutagenized8 and both clones were obtained through
Addgene (Plasmids 25038 and 25039; http://www.addgene.org) (Table 5-2).
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Table 5-2: E-Cadherin 3’-UTR fragment constructs. miR-9 binding site is highlighted
in yellow, the seed region is highlighted in green, and mutated nucleotides are
highlighted in red.
Clone ID

Sequence

WT
CAGGACTTAGAATAGTGCCTAAAGTGCTGCAGCCAAAGACAGAGCGGAACTATGAAAAGTGGGCTTA
Mutated binding site
CAGGACTTAGAATAGTGCCTAAAGTGCTGCAGCGTTTCTCAGAGCGGAACTATGAAAAGTGGGCTTA
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Transfection & Luciferase Activity Analysis
Transient co-transfections of the 3’-UTR fragments cloned into a luciferase
reporter vector along with a renilla luciferase vector for normalization were performed
using TransIT®-LT1 Transfection Reagent (Mirus BIO LLC, Madison, WI, USA). Briefly,
cells were plated such that they would reach approximately 50% density in appropriate
serum-containing media after 24 hours (2.5x104 cells/well in a 24-well plate). The cells
were allowed to adhere for 24 hours, rinsed with 0.5 mL PBS, and serum-containing
media replaced. 0.5 µg of the cloned UTR:vector was mixed with 50 µL of RPMI media
and 1 µg of Renilla plasmid with no serum or additives and 1.5 µL of TransIT ®-LT1
reagent at room temperature for 15 minutes. The solution was added dropwise to each
well, and gently rocked back and forth. The transfections were incubated for 24 hours
under standard cell culture conditions.
Cell lysis and luciferase assays were conducted using the Dual-Luciferase
Reporter Assay System (Promega Corporation). The transfection media in each well
was suctioned off, wells rinsed in PBS, and 100 µL of 1X Passive Lysis Buffer (Promega
Corporation) was pipetted into each well. The samples were rocked for 15 minutes at
room temperature, and the lysate transferred to 1.5 mL microcentrifuge tubes and
frozen at -20°C until analysis. Luciferase and Renilla measurements were taken in a
GloMax® 20/20 luminometer (Promega Corporation). Lysate (20 µL) was added to a
1.5 mL microcentrifuge tube, and 30 µL of firefly Luciferase Assay Reagent II added to
the lysate and luciferase activity measured at a wavelength of 560 nm. Subsequently,
30 µL of Stop & Glo was added, the solution mixed, and renilla luciferase activity was
measured at the 480 nm wavelength.
132

Data Analysis
Data were presented as the mean ± standard deviation. Statistical analyses
were conducted in the Microsoft® Excel software platform, using the independent
Student's t-test, assuming equal variance between the two groups. Statistical
significance was defined as p ≤ 0.05.
Results
Evaluation of miR-9’s effect on the tumorigenic potential of the M12 cells was
performed through stable expression of a specific miR-9 inhibitor. Inhibition of miR-9
had significant effects on migratory and invasive potential of the highly metastatic cell
line as compared to the scrambled control (p <0.0001 for both assays) (Figure 5-3);
however, miR-9 inhibition did not affect cell proliferation rates (data not shown). This is
not surprising, given that the M12 cell line is immortalized with the SV40T antigen,
which binds Rb, a tumour suppressor protein that halts cell cycle progression61,130.
M12 or M12 + miR-9 inhibitor cells (1x106 cells) were subcutaneously injected
into the flanks of nude athymic mice and monitored for tumour volume for up to 47 days.
M12 cells with the miR-9 inhibitor showed a significantly lower level of tumour growth (p
<0.0001) (Figure 5-4). Four of the five M12 injected mice developed tumours, but only
two of the five M12+miR-9 inhibited mice developed tumours, which grew at a slower
rate, resulting in a smaller tumour volume. Intraprostatic injection resulted in 7
metastatic sites for M12-injected mice, while neither of the M12+miR-9 inhibited mice
had any observed metastatic sites by 76 days after injection.
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Figure 5-3: Inhibition of miR-9 significantly reduces migratory and invasive
potential. M12 cells were stably transformed with scrambled control or miR-9 inhibitor,
plated on a ThinCert transwell membrane (with basement membrane added for invasion
assay) and assessed for (A) migratory (p < 0.0001) and (B) invasive potential (p <
0.0001). Data is the mean of 3 independent experiments, each performed in triplicate.
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Figure 5-4: Tumour growth and metastasis is reduced upon miR-9 inhibition. A:
Subcutaneous injections of the respective cell lines into the flank of nude athymic mice.
Tumour reduction was significantly reduced in mice injected with M12 cells stably
expressing the miR-9 inhibitor (p < .0001). Results are reported as the average percent
of tumour volume to the final average M12 tumour volume. N=5 mice for each
treatment. B: Intraprostatic (IP) injection into nude athymic mice resulted in 0
metastatic lesions when miR-9 was inhibited, as compared to 7 lesions in the mouse
injected with M12 cells alone.
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Given the strong evidence for miR-9’s contribution to oncogenic potential in the
inhibition studies, we felt confident that miR-9 must have at least one significant target
that would prevent tumour progression when released from suppression. We therefore
focused our efforts on evaluating miR-9’s proven targets in prostate cancer using the
P69 and M12 progression model.
As a known effector of the epithelial to mesenchymal transition, we were first
interested in evaluating e-cadherin, one of the proven targets for miR-9 (Table 5-1). In
the early tumour cell’s transition from an affixed epithelial cell to a motile phenotype, the
transition in expression from e-cadherin to vimentin is well known and
described22,24,43,152. Previous work in the P69 and M12 cell lines showed that vimentin
is upregulated in the M12 cell line as compared to P69, and that vimentin upregulation
is caused in part by miR-17-3p loss in the M12 cell line (Figure 2-1)25.
Evaluation of E-cadherin message and protein expression was consistent with
being regulated by miR-9 (Figure 5-5). Western blot analysis indicated that e-cadherin
is highly expressed in P69 cells, and considerably lost in the M12 cells. Inhibition of
miR-9 results in a corresponding increase in CDH1 levels. Additionally, RT-qPCR
analysis showed that CDH1 messenger RNA levels are also significantly modulated by
miR-9 (p < 0.03). As in our evaluation of the c-KIT message (Chapter 3), CDH1
messenger RNA must be cleaved by the miR-9/Argonaute 2 complex in order for mRNA
levels to be changed between the cell lines. While there could be and is a considerable
level of complexity between the P69 and M12 cells (Chapter 2), modulation of CDH1
message between the M12 and M12 + mIR-9 inhibitor could be caused by miR-9
cleavage.
136

Relative expression of
CDH1 protein

M12
+miR-9
Inhibitor

P69

M12
CDH1

8
7
6
5
4
3
2

Vim

1
β-Actin

0
P69

B

A

M12

M12+9Inh

Relative CDH1 mRNA
Expression

2.5

C

2
1.5
1
0.5
0
P69

M12

M12+miR-9-Inh

Figure 5-5: messenger RNA and protein levels of CDH1 are increased upon miR-9
inhibition. CDH1 expression in the P69, M12, and M12 stably transformed with vector
expressing miR-9 inhibitor. A: Western blot analysis and B: quantitation. Blot and
quantitation are representative of 5 independent experiments, normalized to β-Actin and
reported as relative to the M12 cell line. C: messenger RNA relative quantitation shows
that mRNA levels are impacted by miR-9, and miR-9 inhibition relieves messenger RNA
and protein levels (p<0.03 for P69 and miR-9 inhibited lines vs. M12). mRNA is
normalized to GAPDH and reported as relative to the M12 cell line. Results are
compiled data from two biological replicates, each performed in triplicate.
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One miR-9 binding site in e-cadherin was identified through an RNAHybrid
analysis of the entire mRNA. This site, found in the 3’-UTR, has been proven to be
directly bound by miR-9 thereby impacting translation21,43. (Figure 5-6). Interestingly,
based on a TargetScan92-94,110 analysis, miR-9 is the only conserved microRNA that
binds to e-cadherin’s 3’-UTR. Transient transfections of luciferase constructs containing
the CDH1 3’-UTR wild type or mutated seed region target (Table 5-2) resulted in loss of
suppression as observed through luciferase activity (Figure 5-7).
As another proven target of miR-9, NF-kB is typically only shown as modulated
when miR-9 suppression is lost, as is seen in carcinomas that show a loss of miR-9
expression153-156,159. In these instances, relief of suppression of NF-kB results in
initiation of transcription of a variety of pro-oncogenic and angiogenic genes. However,
a concomitant decrease in NF-kB is not observed in the cancers in which miR-9 is
overexpressed. Similarly, no difference between NF-kB levels were observed between
the M12 and M12+miR-9 inhibited cells (Figure 5-8). Thus, control of NF-kB was not
pursued further.
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position 1320
target 5'
A GU
C
C 3'
A GCUG
AGCCAAAGA
U CGAU
UUGGUUUCU
miRNA 3' AGUA GU
CUA
5'
mfe: -21.2 kcal/mol

Seed
Region

Figure 5-6: Proven binding site for miR-9 in e-cadherin. Adapted from
RNAHybrid86,87 analysis of CDH1 mRNA (NM_004360.3). Green is the sequence of
miR-9, and red is the complementary region of the 3’-UTR of CDH1.
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Figure 5-7: e-cadherin expression is suppressed by miR-9. M12 cells were
transiently transfected with a firefly luciferase reporter construct containing a portion of
the CDH1 3’-UTR, with the wild type or mutated miR-9 binding seed region (Table 5-3)
along with a renilla luciferase plasmid. Firefly luciferase expression is reported as
normalized to renilla luciferase activity and relative to mutated seed region expression.
Results are the mean of 2 independent experiments, each performed in triplicate. (p
<0.01)
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Figure 5-8: NF-kB levels are not modulated by miR-9. Western blot analysis shows
that NF-kB levels do not change significantly between M12 or M12 cells plus miR-9
inhibitor. Β-Actin included as a loading control. Blot is representative of 3 independent
experiments.
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As a negative regulator of EGFR and JAK signaling pathway, SOCS5, recently
identified as a direct target of miR-9, could attentuate signal transduction and ultimately
transcription of a variety of pro-oncogenic, pro-angiogenic genes157,180. Evaluation of
messenger RNA showed no significant difference in levels between P69, M12, and M12
cells transfected with miR-9 inhibitor; however, western blot analysis indicated a strong
difference in SOCS5 protein levels between the different cell types (Figure 5-9).
Messenger RNA levels do not always change in targets, as perfect seed matches to the
miR and Argonaute 2 are required for cleavage of the message 55.
An evaluation of the SOCS5 mRNA sequence in RNAHybrid against the miR-9
sequence revealed four potential binding sites for miR-9, two of which are located in the
3’-UTR (one proven165), and two located within coding regions of the mRNA (Table 5-3),
all with significant free energy values.
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Figure 5-9: While protein levels of SOCS5 are increased upon miR-9 inhibition,
messenger RNA levels are not significantly different. SOCS5 expression in the
P69, M12, and M12 stably transformed with vector expressing miR-9 inhibitor. A:
Western blot analysis and B: quantitation show that miR-9 inhibition results in increased
levels of SOCS5. Blot and quantitation are representative of 6 independent
experiments, normalized to β-Actin and reported as relative to the M12 cell line. C:
messenger RNA relative quantitation shows that mRNA levels are not significantly
impacted by miR-9. mRNA is normalized to GAPDH and reported as relative to the
M12 cell line. Results are compiled data from three biological replicates, each
performed in triplicate.
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Table 5-3: Potential and proven binding sites for miR-9 in SOCS5. Adapted from
RNAHybrid13,14 analysis of SOCS5 mRNA (NM_014011.4). Green is the sequence of
miR-9, and red is the complementary region of the 3’-UTR of SOCS5. Two of the
potential binding sites are within the 3’-UTR, one of which (shaded in aqua) has been
proven through luciferase 3’-UTR assays and western blot analysis of SOCS515.
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Discussion
In this report, we sought to confirm miR-9’s previously identified status as an
oncomiR, which was based on not only a comparison between the poorly-tumorigenic
P69 and its highly metastatic subline M12, but also other well-established prostate
cancer cell lines, and finally through confirmation using human biopsy samples through
laser-capture microdissection. Inhibition of miR-9 in M12 cells resulted in significantly
reduced migratory and invasive potential in-vitro, as well as reduced tumour growth invivo with no metastatic sites observed in nude athymic mice. Evaluation of the
expression signatures of known miR-9 targets indicated that while NF-kB is not
modulated in this model, e-cadherin and SOCS5 are both regulated by miR-9, resulting
in increased levels when miR-9 is inhibited in M12 cells. Luciferase constructs
containing the e-cadherin 3’-UTR showed that miR-9 suppression of the mRNA is
effective in the prostate cancer model.
E-Cadherin message and protein levels are suppressed by miR-9
Dysregulation of miR-9, although initially assumed as being overexpressed in
carcinoma in general, has been shown through recent literature to be cancer typespecific. In breast cancer, neuroblastoma and prostate cancer, miR-9 is observed to be
up-regulated843, whereas it is downregulated in metastatic melanomas. In these cell
types, miR-9 suppresses expression of NF-ĸB, which results in increased levels of
Snail1 and subsequent activation of e-cadherin160. Interestingly, higher levels of miR-9
have been associated with a better outcome in ovarian cancer, where it was shown to
directly target BRCA1159.
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The difference in miR-9 expression by cancer type could be due to promoter
activity of miR-9, whether through PROX1, Snail1, or hypermethylation. miR-9 is also
down-regulated in nasopharyngeal carcinoma (NPC), where it is implicated in the
inflammatory response, specifically for Interferon-induced genes161. In this case,
hypermethylation of the miR-9 promoter results in reduced transcription, resulting in loss
of CXCR suppression, a chemokine receptor that has been shown to be expressed in a
number of different tumour types162. Recently, a second report showing the direct effect
of miR-9 on CXCR identified that this loss of suppression resulted in the accumulation
of β-catenin through the Wnt pathway22,163, and the subsequent transcriptional
activation of JAK/STAT proliferative pathways164.
E-cadherin is known to sequester β-catenin, which also works to assist in
dynamically connecting the adherens junctions to the cytoskeleton21,22,151. Loss of ecadherin through miR-9 suppression would free β-catenin from the adherens complex,
permitting its movement into the nucleus, where it can interact with the zinc finger
transcriptional factors of the Tcf/Lef family to activate transcription of pro-metastatic,
pro-angiogenic genes including VEGFA, Siamois, c-Myc and cyclin D122,43 (Figure 510). Loss of e-cadherin has also been shown to reduce phosphorylation of β-catenin,
which results in increased stability by blocking movement to the proteasome for
degradation152.
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Figure 5-10: miR-9’s mode of action on tumour progression through e-cadherin.
In the presence of miR-9 (upper panel), e-cadherin message is cleaved and
suppressed, resulting in less protein production. This allows for accumulation of βcatenin (green “L”), which can then diffuse into the nucleus, activate transcription factors
and drive transcription of pro-survival, pro-proliferation genes including c-Myc and
Cyclin D1. c-Myc then initiates additional miR-9 message through a positive feedback
signal. In the noncancerous tissue (lower panel), e-cadherin is produced and
sequesters β-catenin, preventing activation of downstream transcriptional events.
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SOCS5 protein levels are suppressed by miR-9
As a recently identified direct target for miR-9, loss of the tumour suppressor
SOCS5 results in increased and prolonged activation of JAK/STAT pathways. The full
function and target RTKs and JAK/STATS for SOCS5 is still unknown. However, it
shares strong homology with the other members of the SOCS family, which are known
to interfere with both JAK kinase and STAT protein activity, as well as promote their
degradation through ubiquitination157,158. In the original report identifying miR-9 as a
regulator for SOCS5 when overexpressed, SOCS5 expression was shown to be downregulated concomitant with increased JAK1, STAT1 and STAT3 phosphorylation
levels165. SOCS transcription is also known to be part of a negative feedback loop, in
that STAT binding sites activate SOCS5 transcription for ultimate suppression of signal
transduction157,158. Even though the JAK/STAT pathway has been shown to be
activated in M12 cells60,61,67, the negative feedback loop that would ultimately attenuate
JAK/STAT signaling is being prevented through suppression of SOCS5, as we have
shown that both SOCS5 mRNA and protein levels are reduced in M12 cells compared
to the parental P69 (Figure 5-11).
Conclusions
This report has confirmed our previous work identifying miR-9 as an oncomiR in
prostate cancer. The action of miR-9 is multifaceted; through suppression of miR-9, the
e-cadherin that makes up the cell-cell interactions characteristic of an epithelial lineage
is suppressed; thus, promotion from a stationary, embedded cell to a more motile
phenotype is stimulated, as is readily observed in the EMT transition for a variety of
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Figure 5-11: miR-9 overexpression inhibits SOCS5, causing increased signal
transduction through the JAK/STAT pathways. In the presence of miR-9 (left),
SOCS5 message is cleaved and translation suppressed, resulting in less protein
production. This allows phosphorylation and signal transduction, resulting in p-STAT
transcriptional activation of pro-survival, proliferation, and invasion/mestatasis
oncogenes. In the normal tissue without miR-9 overexpression (right), SOCS5 is
produced and reduces or blocks phosphorylation of JAK kinase and STAT while also
promoting ubiquitination, thus attenuating the JAK/STAT signaling cascade, and
lowering activation of transcriptional events.
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cancers. Loss of e-cadherin also results in release and stabilization of β-catenin, which
can then move to the nucleus and activate transcription of VEGFA, c-Myc, Cyclin D1,
and other pro-angiogenesis, proliferative genes. Given that c-Myc is a known activator
of miR-9-3, this too represents a feedback loop that could further induce even more
miR-9 expression. Finally, action of miR-9 on SOCS5 results in loss of attenuation of
the JAK/STAT pathways, which ultimately transduces growth signals to promote cell
survival and proliferation. This is the first report to show a multi-targeted mode of action
of miR-9 in a cancer. Moreover, results observed in-vivo indicate that both tumour
growth and metastases are severely impacted by miR-9 inhibition (Figure 5-4). For
those carcinomas in which miR-9 is overexpressed, inhibition of miR-9 could be a very
effective therapeutic target, both in early neoplasias to prevent the EMT transition, but
also in advanced, aggressive cancers to reduce proliferation and combat metastasis.
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Chapter 6:
Summary and Future Directions
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Dysregulation of microRNAs to drive tumour progression and metastasis is
receiving a great deal of attention, as canonical pathways are seen to be regulated at
key protein nodes through miR suppression67. This can result in either suppression of a
tumour suppressor protein through overexpression of the miR (oncomiR), or activation
of a previously suppressed oncogene through loss of a tumour suppressor miR.
The prostate cancer cell line progression model developed by Dr. Joy Ware is
valuable for identifying modulated miRs and downstream pathways in prostate cancer,
as the normal epithelial SV40T immortalized P69 cell line is poorly tumorigenic and not
metastatic61. The M12 subline, produced by three subsequent injections of tumour cells
into nude athymic mice, is highly tumorigenic and metastatic in nature 60. These two cell
lines constitute a unique model in prostate cancer research, in that they have a common
genetic background, and presumably selection of the M12 subline mimics a human
tumour progression pathway.
Using the P69 and M12 progression model, our laboratory has been able to
identify a variety of dysregulated microRNAs and their corresponding target mRNAs,
and identify key impacted pathways that progress the neoplasia. These findings have
been confirmed through in-vitro modulation of the miRs, showing changes in
tumorigenesis, for the most part, metastases, and migratory capabilities, but also
through in-vivo work in mice. Moreover, their dysregulation was confirmed in analysis of
prostate cancer biopsies.
In this dissertation, we performed a global miR analysis to identify dysregulated
miRs between the P69 and M12 cell line, and then confirmed those expression
differences in other well-used prostate cancer cell lines as well as laser-capture
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microdissected samples from prostate biopsies (Chapter 3). miRs 9 and 147b were
identified for further analysis based on their consistently high level of expression.
miR-147b was identified as a potential oncomiR through this work. Inhibition of
miR-147b was found to affect not only proliferative, migratory and invasive capabilities
of M12 cells, but also reduced tumour growth in male nude athymic mice. AATF was
identified as a potential target through western blot and mRNA analysis, along with
identification of potential miR-147b binding sites within the mRNA. AATF has been
well-established as being involved in cell-cycle progression139,143. Its loss has
previously been shown to activate p21 transcription, which is a known inhibitor of cellcycle progression136.
Similarly, miR-9 was found to be overexpressed in prostate samples and to
function as an oncomiR by affecting the epithelial to mesenchymal transition through
suppression of e-cadherin. As e-cadherin assists in maintaining the integrity of the
epithelial cell to cell contact, loss of e-cadherin would result in destabilization of the cell
from the rest of the tissue. Loss of e-cadherin results in increased levels of free βcatenin. β-catenin can then translocate to the nucleus and assist in activation of
transcription of proliferative genes, including Cyclin D1 and c-Myc21,22,43 (Chapter 5).
Inhibition of miR-9 resulted in not only reduction of migratory and invasive potential, but
significant reduction of tumorigenesis and metastases, as evaluated through in-vivo
work with male nude athymic mice.
Building on previous work on miR-17-3p, reverse phase microarray analysis
(RPMA) comparing the parental P69 and M12 subline showed a dramatic increase in c-
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Table 6-1: dysregulated microRNAs identified in prostate cancer through the
P69-M12 progression model

microRNA

Target Protein/mRNA(s)

Pathways implicated

miR-17-3p25

Vimentin, c-KIT

EMT transition, AKT, ERK,
JAK/STAT

miR-125b67

ErbB2 & 3

AKT

miR-147b

AATF

Cell Cycle progression, p21

miR-9

E-cadherin, SOCS5

EMT transition, cell cycle,
JAK/STAT, β-catenin, c-Myc
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Figure 6-1: Proposed mechanism for a multi-modal effect of dysregulated miR
effects on tumour progression. Overexpression of miR-9 results in loss of SOCS5,
an attenuator of JAK-STAT signal transduction, and of e-cadherin, an adhesion protein
that maintains epithelial sheet integrity, as well as sequestration of β-catenin, a
transcriptional activator of c-Myc and Cyclin D1. Likewise, overexpression of miR-147b
results in the loss of AATF, and subsequent loss of p21 transcription, an inhibitor of
CDK/Cyclin activated cell cycle progression. Loss of miRs-17-3p and 125b both result
in increased transcription and levels of RTK growth factor receptors c-KIT and
ERBB2/ERBB3, which increases pro-proliferative and survival signal transduction. Loss
of miR-17-3p also promotes the EMT transition through relief of vimentin transcriptional
suppression, an intermediate filament characteristic of the mesenchymal phenotype.
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KIT in the M12 cells67. This increase in c-KIT, a stem cell growth factor receptor
tyrosine kinase, was ablated in the M12 cells expressing miR-17-3p. We identified two
binding sites in c-KIT’s 3’-UTR that we confirmed as being directly targeted by miR-173p (Chapter 2). Two additional binding sites, one in the 5’-UTR and the other in an
exon, were identified for further analysis.
The summation of this laboratory’s work in identifying modulated microRNAs in
prostate cancer has progressed such that four microRNAs have been identified as
contributing to the progression of the prostate tumour (Table 6-1). Evaluation of the
impacted pathways show that each is vitally connected to key modulators and/or
pathways known to affect tumour progression or cell proliferation. While admittedly
some miRs (miR-9) were chosen based on their known targets and connectivity and
therefore some bias may be in place there, others (miR-147b) were chosen based on
their high (or low) consistent expression, with little to no foreknowledge of their target
proteins.
Taken together, we know that through both modeling and patient samples,
prostate cancer has a reduced expression of miR-17-3p25 and miR-125b67. Loss of
miR-17-3p causes relief of suppression for vimentin and c-KIT, with a concomitant
increase in EMT transition, and activation of growth signal transduction pathways,
thereby enhancing subsequent transcription of proliferation/survival genes (Figure 6-1).
On the other hand, miRs 147b and 9 are highly upregulated, each also contributing to
the EMT transition as well as growth and proliferation signaling pathways.
Consequently, while each miR tends to be evaluated on a case-by-case basis, it is the
accumulation of all of these dysregulations that contribute to tumour progression and
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the transition to an invasive phenotype in prostate cancer. Thus, the sum of the parts
working synergistically is greater than each component working alone.
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Chapter 7:
An evaluation of the stability of microRNAs in forensically relevant
biological fluids
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While forensic DNA analysis has reached a level of maturity in the Forensic
Science field with regards to the sophistication of the techniques and confidence in the
results, the equally important question of body fluid identification has lagged behind,
and could still be considered to be in a primitive state. Current crime scene and inlaboratory methods utilize detection methods that exploit the properties of each
biological fluid (e.g. phenolphthalin or TMB testing for blood, amylase detection for
saliva, and urease tests for urine), but validated identifying techniques are largely
limited to microscopic methods (i.e. identification of spermatozoa) or immunological
methods, as seen in the widely used immunochromatographic commercial tests for
blood, semen, and other biological fluids. Thus, while there is widespread confidence in
the DNA profile generated, there is often significantly less assurance in the identity of
the body fluid that the DNA profile was developed from. It is common during trials for
attorneys to categorically accept the STR analysis, but probe the forensic scientist on
the source of the DNA that generated the profile. Because of this dichotomy, significant
efforts have been made over the past ten years in order to develop forensic serological
techniques of a more discriminatory nature. There are three main areas that can be
exploited for molecular methods for body fluid identification: the genome, the
transcriptome, and the proteome. Each has been subject to a great deal of research.
Recently, there has been some work in the forensic science field in regards to
exploring microRNAs (miRs) for a molecular-based, forensic body fluid identification
method. MiRs are small structures that are transcribed as larger precursors (60-100
nts) that immediately form a stem-loop structure with incomplete base-pairing and
flanking nucleotides34. Processing of the immature miR is accomplished through
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excision of the loop, resulting in a mature miR of 19-23 nucleotides long. There are no
known postprocessing modifications, and thus miRs are simpler, and potentially less
problematic for detection than proteins and mRNAs. MicroRNAs show distinct promise
for forensic body fluid identification on several grounds. There is significant literature
that some miRs are differentially expressed, and in fact are involved in embryonic stem
cell development and tissue differentiation35,166,167. They are found in extracellular
fluids166, and thus the discovery and application of unique miRs to forensically relevant
body fluids is a distinct possibility.
Because of their small size and lack of a poly-A tail, miRs are inherently less
susceptible to degradation than mRNA. Additionally, miRs are very hardy, and can be
recovered from highly compromised samples including formalin-fixed paraffin
embedded (FFPE) tissue25. In serum, miRs have been shown to survive harsh
conditions such as boiling, low or high pH, cycles of freeze-thaw, and extended
storage56. In the clinical arena, miRs have been shown in urine, and potential markers
for bladder cancer have been evaluated168,169. A recent study evaluated liquid semen,
kept at room temperature for up to seven days, and frozen and thawed up to eight
times, and found minimal differences in levels of three miRs evaluated168. Urine stability
was evaluated in up to four consecutive freeze-thaw cycles, and no significant
difference was found in mIR-1 and miR-16 levels170.
There is considerable evidence that many miRs are encapsulated in an
exosome, which, depending on the microRNA and the secretion process, could be
membrane- or protein-based58,171. Because of this, recent studies have shown that
samples can even be treated with RNase enzymes and the encapsulated miRs are still
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detectable56. This implies a high degree of stability of the species, and therefore, a very
good possibility that if body-fluid specific miRs are found and described, a very robust
miR panel for forensic body fluid identification could be developed.
Recently published studies examining miRs for forensic body fluid ID purposes
utilized microarray screens and/or RT-qPCR, with varying results167,172-174. A panel that
can discriminate between blood, semen, saliva, vaginal secretions, and menstrual blood
has already been described by Hanson et al172,175. Further, Zubakov et al found that
miRs could be detected using qPCR from just picograms of total RNA, far below the
known detection limit of mRNAs173. Recent reports have shown that miRs are
detectable and coextracted in silica-column based DNA extracts at a similar level to
RNA extracts176,177. Because of the preliminary results reported from these authors, it is
clear that miRs are detectable from forensic samples, and that it is an area that should
be evaluated thoroughly. The purpose of this work was to evaluate the stability of
microRNAs in blood, semen, urine, and saliva under the harsh treatment conditions that
evidence samples could be subjected to at the crime scene.
Methods & Materials
Sample Collection & Treatment
Blood, urine, semen, and saliva were collected from volunteers under an
approved human subjects research protocol. One body fluid collection from a single
individual was used for all treatments, in order to eliminate variation seen in person-toperson and collection-to-collection miR levels. Urine, semen, and saliva were deposited
into sterile collection cups and 50 µL (semen, saliva) or 100 µL (urine) was applied to
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cotton swabs or cloth. Blood was collected into a Vacutainer® containing EDTA
(Beckton, Dickinson & Company, Franklin Lakes, NJ), inverted for 15 seconds, and 50
µL immediately applied to cotton swabs or cloth. All samples were allowed to dry for 24
hours, and swabs or stains cut and placed into 1.5 mL microcentrifuge tubes, and
stored at -20ºC before and after subjection to treatment.
Samples undergoing irradiation were placed on a Bio-Rad 464BR ultraviolet
transilluminator (Bio-Rad Laboratories, Hercules, CA) for 4 hours. Samples undergoing
heat treatment were incubated at 55ºC or 95ºC for 0.5, 1, 2, 4, or 24 hours. For
samples exposed to chemical conditions, 100 µL of 87 mM or 870 mM sodium
hypochlorite (1:10 dilution and full-strength household bleach, respectively), glacial
acetic acid, or household dishwashing detergent were applied to the samples. The
microcentrifuge tubes containing the treated samples were left open to air dry for 72
hours. The samples were then stored at -20ºC until isolation.
RNA Isolation and Analysis
RNA isolation was conducted using the Qiagen miRNeasy mini kit (Qiagen N.V.,
Venlo, The Netherlands). Briefly, the entire swab or fabric cutting was placed in 700 µL
of QIAzol lysis reagent, and incubated for 5 minutes at room temperature, vortexing
every minute. The swab or cutting was then placed in a DNA IQ™ Spin Basket
(Promega, Madison, WI, USA), and centrifuged at 13000xg for 3 minutes. The resultant
lysate was then processed according to protocol and total RNA eluted in 30 µL of
RNase-free water. RNA was quantified using the NanoDrop ND-2000 UV
Spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA).
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Quantitative reverse transcription was carried out via the qScript™ microRNA
Quantification System (Quanta Biosciences Inc., Gaithersburg, MD).

Reverse

transcription was carried out according to the manufacturer’s protocol using 7 µL of
RNA extract. qPCR reactions were prepared in triplicate for each sample using a
modified protocol: 6.25 µL of PerfeCTa SYBR Green SuperMix (2X), 0.25 uL (2.5 µM)
PerfeCTa microRNA Assay Primer (miR-16, 21, or 24), 2 µL of cDNA reaction, and 4 µL
of nuclease-free water. Thermal cycling was conducted on the Life Technologies Prism
7300 instrument (Life Technologies, Foster City, CA) using the following parameters:
95ºC for 2 minutes, followed by 40 cycles of 95ºC for 5 seconds, 60ºC for 15 seconds,
and 70ºC for 30 seconds (data collection). qPCR analysis was conducted using SDS
software, v1.3.1 (Life Technologies).
All treatments were performed on a minimum of two treated samples, with 3
technical (qPCR) replicates for each treated sample, with the exception of the fullstrength bleach, detergent, and acetic acid treatments, which had one biological sample
with a minimum of 3 technical replicates.
Data Analysis
In order to determine relative changes in sample integrity, a dCT was calculated
in which the CT of the treated sample was subtracted from the CT of the untreated
control of the same body fluid. Given that the literature regarding normalization miRs
for body fluids is variable, and effect on integrity is as yet unknown, this is the most
discriminating measure. Using identical RNA extraction, reverse transcription, and
qPCR parameters provide a consistent comparison of miR quality from treated sample
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to control. An unpaired two-tailed t–test was applied to determine significance between
treated and untreated samples.
Results & Discussion
RNA Isolations
Total RNA yield was not affected by any treatment method (data not shown).
This is consistent with a previous report by Setzer et al178, in which mRNA stability in
environmentally challenged samples was evaluated.
Heat Treatment
Blood, treated for any length of time at both 55 and 95°C, was highly resistant to
degradation, with no failed reactions (Figures 7-1a & b). miR-16 levels are high in
blood, which resulted in low CT values regardless of treatment. Saliva too was
remarkably stable under heat treatment at 55°C (not tested at 95°C) and was always
detectable. However, seminal fluid and urine showed themselves to be more
susceptible to the degradative effects of heat treatment. Semen had a 92.8% failure
rate (4 biological replicates, 14 technical replicates) at 30’, 50% failure rate at 1 hour,
and 0% failure rates at 2 and 24 hours. This pattern is seen in several instances of
treatment, and is cause for deliberation, as it too, was seen in multiple biological and
technical replicates. Urine, as a high-volume, low cell-content fluid, understandably has
low levels of miRs to begin with (CT range of positive control miR-16 – 32.4 ± 1.4).
Thus, any degradation can quickly result in loss of signal. Thus, sample failure rates at
1 and 2 hours of 55°C were not unexpected. What was unexpected, however, were
excellent amplification of miR-16 in urine at 24 hours at 55°C, and 100% sample
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success at 1, 2, or 24 hours at 95°C. As these results are somewhat more variable than
expected, several biological and technical replicates of the failed treatments were
repeated; however, results were consistent and since native miR-16 levels are low in
untreated urine, not statistically significant.
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Figure 7-1: microRNA stability under heat conditions over time. Relative miR-16
levels as determined by the difference in CT from treated sample to control of the same
body fluid. A: 55°C Heat Treatment. Blood and saliva miR levels did not change
significantly at 30 and 60 minutes, but differences were significantly higher at 2 and 24
hours (p<0.05). Urine and semen had significantly higher dCT levels and failed
reactions. N≥2 biological and 6 technical replicates for each treatment. B: 95°C Heat
Treatment of blood and urine (semen and saliva not tested). Differences in urine were
not statistically significant; however, all differences in blood were statistically significant
(p<.005). No failed reactions. N=1 biological and minimum 3 technical replicates for
each treatment.
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Ultraviolet Treatment
All body fluids tested were highly resistant to ultraviolet treatment, yielding
detectable miR levels. Blood and semen CTs were statistically higher than the control
(p<.01), but still detectable with no reaction failures. (Figure 7-2A). As seen in heat
treatment, saliva samples actually had a modest increased in miR levels based on C T
values, but the results were not statistically significant. While there is very little research
in the area of UV damage to RNAs, and none for small RNAs, the primary mode of
action for ultraviolet damage is the fusion of pyrimidine doublets, and ultraviolet
exposure has been shown to impact RNA in pure extracted form179. However, this is
not relevant to the matrix of a dried body fluid sample; ultraviolet light has been shown
to affect mRNA levels only after 90 and 180 days of exposure from mock forensic
samples178.
Chemical Treatment
Bleach treatment resulted in two widely variant results. While blood and urine
were consistently resistant to both diluted and household strength bleach application,
semen and saliva proved vulnerable, resulting in a majority of sample failures at 10%
bleach treatment, and 100% failures at full-strength bleach application (Figure 7-2B).
This is enigmatic, as application with glacial acetic acid (pH ~2.4) yielded minimal
difference from the control for all body fluids (Figure 7-2C). Given the fact that RNA is
more stable under slightly acidic conditions than DNA, it would be interesting to
evaluate samples that had been exposed to similar conditions for DNA quantity and
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Figure 7-2: microRNA stability under various conditions. Relative miR-16 levels as
determined by the difference in CT from treated sample to control of the same body
fluid. A: Ultraviolet exposure. miR levels were minimally affected by ultraviolet
exposure. Only blood and semen showed statistically significant differences vs. control
(p <0.01) N=2 biological and ≥5 technical replicates for each treatment. No failed
reactions were observed. B: Bleach treatment. 10% bleach: Urine miR levels did not
change significantly (p=0.263), and blood was significantly affected (p<0.001) but still
readily detectable. Saliva and semen had mainly failed reactions N≥2 biological and 6
technical replicates for each body fluid treatment. Full-strength bleach: Urine was not
significantly affected by whole bleach treatment (p=0.483), but blood, semen, and saliva
were significantly affected (p<0.001). While blood miR-16 levels were affected by
treatment, but still detectable, saliva and semen were degraded to the point that miR-16
was undetected. N=1 biological and 3 technical replicates for each body fluid treatment.
C: Acid and Detergent treatment. Glacial Acetic Acid: All body fluids were detectable,
with no significant deviation from positive control detection threshold. N=1 biological
and 3 technical replicates for each body fluid treatment. Dishwashing detergent: Saliva
and urine were readily detectable, with no significant deviation from positive control
detection threshold. Blood too was easily detectable, but significantly affected (p=0.03).
Semen had a 50% failure rate with dishwashing detergent application. N≥1 biological
and 3 technical replicates for each body fluid treatment.
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STR profile analysis. Again, saliva seemed to gain miR levels during treatment as
compared to the control (difference not statistically significant).
Application of dish detergent was performed for multiple reasons. First, it is a
canonical treatment for forensic samples, given the fact that crime scene cleanup by
perpetrators are typically attempted using common and convenient household
chemicals. Secondly, it stands to reason that because some secreted miRs are
encapsulated within a microvesicle, which contains large amounts of cell membrane
lipid components, or co-transported with HDL particles56-59, stability could be affected by
disrupting such particles and exposing the microRNAs. Interestingly, blood, urine, and
saliva were minimally affected by detergent application, with saliva again yielding better
amplification results than the control (Figure 7-2C). However, semen yielded only a
50% success rate (2 biological, 6 technical replicates).
Overall miR stability (by body fluid, different miRs)
Three candidate microRNAs were evaluated for stability purposes; miR-16, 21,
and 24. These miRs are commonly detected in tissues and body fluids, were evaluated
in all body fluids and found to be expressed at high levels. miR-16 was used for this
study, but miR-21 and miR-24 were also evaluated in a number of treatment types, and
were consistent with the results seen in miR-16 (data not shown). This indicates that
degradation seen in this study is likely to be representative of the integrity levels of the
miR population in the body fluids assessed. In an effort for consistency, miR-16 was
used across all body fluids; however, highly expressed miRs in each body fluid could be
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Figure 7-3: Overall Stability Parameters. Compiled average CT data for all
treatments, all replicates. As miR-16 was highly abundant in blood, even severe
treatment resulted in detectable miR levels. As the abundance of the miR decreased
(as determined by CT), treatment resulted in more amplification failures in a 40-cycle
amplification.
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found and used as a better indicator, as they would likely result in less failed reactions
in low-abundance body fluids such as urine.
Conclusions
This study sought to characterize the stability of microRNAs for forensic samples.
Given the explosion in recent interest in microRNAs, it is important to understand the
limitations, if any, to the forensic analysis of a new species of nucleic acid. Overall, the
microRNAs assayed, as an indicator of the species as a whole, were remarkably stable,
with detection in the majority of treatments (Figure 7-3). The microRNAs present in
blood and saliva were both more abundant and robust, and were detectable throughout
all treatments. Urine and semen were more susceptible to treatment, but were
detectable in the majority of treatment scenarios. Larger volumes of each body fluid
could have been used, but it was felt that keeping the volume small was more indicative
of the sample sizes often seen in forensic evidence. Given that the miRs tested were
very readily and consistently detectable in such small samples, it is highly possible that
stability is even better than seen in these results, once more abundant and indicative
miRs are identified for each body fluid. The results from this study underscore the need
to comprehensively evaluate the miRnome in each forensically relevant body fluid.
Other researchers have begun to do this through the use of microarray qRT-PCR, but
there are still inconsistencies between research laboratories in regards to which miRs
are diagnostic for the primary body fluids. The secondary, accessory body fluids have
not been assayed (urine, feces, sweat) in most cases. Additionally, there is
disagreement and confusion, not only in the forensic community, but also within the
analytical and research community, regarding appropriate endogenous markers for
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miRs in body fluids. Certainly once there is more standardization and better means of
normalization, a better evaluation and identification of unique markers for each body
fluid can be undertaken.
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APPENDIX 1: Expression Analysis of modulated microRNAs
Table 1: Average CT values of miR RT-qPCR selected for further analysis in
prostate cell lines. Further processing included normalization of all CT values using
RNU48, which reached the cycle threshold consistently around 19-20 in the RNA of all
cell lines tested. Each value is the average of a minimum of one biological replicate
with technical triplicates. Undet = undetected to 40 amplification cycles. *For the miR299-5p M12 evaluation, RNU48 had an atypical amplification plot (CT of ~24).
cell line
P69
WPM1
BPH-04
M2182
M12
F6
DU145
PC3
LnCaP-L
LnCaP-C4
LnCaP-C4-2
LnCaP-P4

133a
36.217
undet
35.605
undet
34.110
undet
--37.430
----undet
---

133b
34.750
36.093
31.603
34.823
32.053
34.703
32.397
33.910
---------

9
37.587
33.270
--34.670
30.777
35.770
25.647
27.210
---------

622
34.667
35.567
--34.430
36.577
36.990
36.320
34.370
---------

146a
32.780
----27.200
38.860
36.625
-------------

199a3p
34.177
----33.640
34.070
32.845
-------------

147b
35.560
33.365
--33.977
31.977
33.010
30.967
27.960
---------

cell line
P69
WPM1
BPH-04
M2182
M12
F6
DU145
PC3
LnCaP-L
LnCaP-C4
LnCaP-C4-2
LnCaP-P4

2993p
34.670
34.460
--36.747
undet
undet
undet
undet
---------

221
21.210
------21.453
25.047
-------------

127-5p
33.800
----37.390
undet
undet
-------------

127-3p
27.960
----36.880
undet
35.500
-------------

299-5p
31.877
26.327
--34.990
34.375*
35.625
undet
34.190
---------

147
36.650
----35.830
undet
37.695
-------------

144
undet
----37.563
undet
34.885
-------------
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488
35.997
undet
undet
undet
undet
undet
undet
undet
29.580
30.960
29.485
32.785

Table 2: miR expression of all cell lines analyzed. miR-levels were normalized to
RNU48 (dCT). ---: not tested
cell line
P69
WPM1
BPH-04
M2182
M12
F6
DU145
PC3
LnCaP-L
LnCaP-C4
LnCaP-C4-2
LnCaP-P4

133a
17.04
21.14
16.42
20.41
11.99
21.03
--16.32
--20.86
21.77
---

133b
13.73
15.92
11.78
14.70
12.41
14.30
13.71
13.36
---------

9
16.57
12.79
--15.24
11.13
15.53
5.23
5.99
---------

622
15.51
15.08
--15.00
16.93
16.75
15.90
13.15
---------

146a
13.63
----7.77
19.21
16.38
-------------

199a-3p
15.02
----14.21
14.42
12.60
-------------

147b
16.41
12.88
--14.54
12.33
12.77
10.55
6.74
---------

cell line
P69
WPM1
BPH-04
M2182
M12
F6
DU145
PC3
LnCaP-L
LnCaP-C4
LnCaP-C4-2
LnCaP-P4

2993p
15.52
13.98
--17.31
20.35
19.76
19.58
18.78
---------

221
2.03
------1.64
6.07
-------------

127-5p
14.30
----17.96
16.92
19.76
-------------

127-3p
8.46
----17.45
16.92
15.26
-------------

299-5p
12.38
5.84
--15.56
--15.32
19.58
12.97
---------

147
17.50
----16.40
20.35
17.45
-------------

144
20.50
----18.13
15.96
14.64
-------------

191

488
16.82
21.14
20.82
20.41
21.52
21.03
20.86
18.89
11.02
11.82
11.26
13.45

Table 3: Relative miR expression of laser-captured microdissected tissues from 5
patients. miR-levels were normalized to RNU48, and expression level calculated
relative to the benign tissue of the same patient. Undet = both benign and the tissue
were undetected to 40 amplification cycles. Red shading indicates that the miR in
question was undetected in the benign sample to 40 cycles, and green indicates that
miR in question was undetected in the tissue type being tested. miR-133b was not
examined due to inconsistent readings in the cell line analysis.
Patient
7

Notes on sample

09-225

G4+/G6

09-362

G3/G4

10-014V002

9

144

221

488

299-3p

299-5p

199a-3p

Tumour

2.622

nt

0.245

Undet.

Undet.

3.726

nt

Tumour

Undet.

Undet.

0.4454

Undet.

0.4070

Undet.

0.4983

Tumour

0.295

Undet.

3.031

Undet.

Undet.

Undet.

0.578

Stroma

0.551

Undet.

26.446

Undet.

Undet.

Undet.

25.194

Lymph

0.547

34.416

9.514

Undet.

Undet.

Undet.

0.809

Tumour

78.339

Undet.

1.939

Undet.

Undet.

22.445

nt

Stroma

nt

nt

6.119

nt

nt

nt

nt

Lymph

nt

Undet.

1.063

nt

nt

nt

nt

Tumour

3.873

Undet.

0.364

nt

0.833

Undet.

nt

Venous

Undet.

214.277

nt

nt

nt

nt

nt

622

127-3p

127-5p

133a

146a

147b

147

Tumour

0.341

0.477

0.009

0.585

nt

0.416

nt

Tumour

0.1504

0.2803

0.5430

0.8878

0.4132

4.6000

nt

Tumour

6.521

2.868

1.000

5.816

Undet.

3.482

Undet.

Stroma

1.167

0.288

1.000

40.317

Undet.

Undet.

Undet.

Lymph

1.320

0.186

1.000

0.658

Undet.

Undet.

Undet.

Tumour

1.495

2.845

0.017

2.959

nt

16.507

nt

Stroma

nt

2.809

nt

4.713

nt

nt

nt

Lymph

nt

nt

nt

nt

nt

nt

nt

Tumour

2.621

0.331

Undet.

1.067

nt

19.973

nt

Venous

nt

1.382

Undet.

2.508

nt

Undet.

nt

10-036V001

early
stage

Patient
7

Notes on sample

09-225

G4+/G6

09-362

G3/G4

10-014V002
10-036V001

early
stage
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